_unit_id,_created_at,_id,_started_at,_tainted,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,baselinedec,e1,e2,rel-type,sent_id,sentence,term1,term2
788660702,9/15/2015 10:42:08,1738660341,9/15/2015 10:41:44,false,instagc,1,18960682,GBR,U2,Annan,92.18.213.181,[LOCATION],[LOCATION],appearing in,N/A,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 10:43:18,1738660637,9/15/2015 10:43:02,false,clixsense,1,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],expected pattern by,n/a,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 10:44:59,1738660983,9/15/2015 10:44:45,false,elite,1,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],followed,N/A,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 10:51:38,1738662580,9/15/2015 10:50:52,false,clixsense,1,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],appearing,N/A,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 10:53:04,1738662908,9/15/2015 10:52:25,false,elite,1,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],RESISTANCE,Treat,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 10:53:37,1738663038,9/15/2015 10:53:23,false,elite,1,30659551,USA,VA,Manassas,207.244.89.77,[SIDE_EFFECT],[SIDE_EFFECT],followed,N/A,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 10:56:41,1738663754,9/15/2015 10:56:01,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,[MANIFESTATION],[MANIFESTATION],appearing in,N/a,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 11:04:36,1738665450,9/15/2015 11:04:21,false,elite,1,30659615,USA,"","",162.250.145.234,[SIDE_EFFECT],[SIDE_EFFECT],followed,N/A,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 11:29:49,1738676749,9/15/2015 11:28:42,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",followed the expected pattern by,N/A,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 11:34:41,1738678877,9/15/2015 11:33:50,false,prodege,1,27934334,GBR,C8,Croydon,81.159.60.206,[ASSOCIATED_WITH] [LOCATION],"[LOCATION]
[ASSOCIATED_WITH]",appearing in,N/A,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 11:37:05,1738679994,9/15/2015 11:36:42,false,neodev,1,12115558,USA,OH,Twinsburg,98.27.164.131,[LOCATION],[LOCATION],by appearing,N/A,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 11:58:01,1738689073,9/15/2015 11:57:16,false,elite,1,31883685,GBR,"","",79.66.254.237,[ASSOCIATED_WITH],[ASSOCIATED_WITH],appearing in,n/a,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 12:16:59,1738695422,9/15/2015 12:15:47,false,neodev,1,33758777,USA,"","",38.95.108.251,[SYMPTOM],[SYMPTOM],appearing,N/A,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 12:18:42,1738696143,9/15/2015 12:17:48,false,clixsense,1,17950689,GBR,L9,Sheffield,146.200.192.103,[SYMPTOM],[SYMPTOM],CLINDAMYCIN,NONE,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660702,9/15/2015 12:33:52,1738701112,9/15/2015 12:31:12,false,tremorgames,1,32655637,CAN,ON,Markham,135.23.223.26,[MANIFESTATION],[MANIFESTATION],expected pattern by appearing,N/A,69,0,86,85,22,RO-may_treat,820127-FS1,CLINDAMYCIN RESISTANCE followed the expected pattern by appearing in A STRAIN OF STAPH,A STRAIN OF STAPH,CLINDAMYCIN RESISTANCE
788660703,9/15/2015 09:26:23,1738639663,9/15/2015 09:25:59,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[PREVENTS],[PREVENTS],prevalence of,N/A,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 09:39:57,1738643901,9/15/2015 09:38:28,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[CONTRAINDICATES],[CONTRAINDICATES],DRUG RESISTANT,N/A,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 09:46:37,1738645704,9/15/2015 09:46:18,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[OTHER],[OTHER],ranged from for,n/a,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 09:50:19,1738646612,9/15/2015 09:49:39,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ranged from,N/A,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 09:54:48,1738647929,9/15/2015 09:54:22,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prevalence,n/a,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 10:01:33,1738649587,9/15/2015 10:00:07,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],The prevalence SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID,N/A,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 10:02:35,1738649867,9/15/2015 10:02:04,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ranged from,N/A,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 10:06:32,1738650992,9/15/2015 10:05:44,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ranged from,N/A,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 10:08:33,1738651574,9/15/2015 10:07:22,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],prevalence,N/A,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 10:10:02,1738652009,9/15/2015 10:09:27,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prevalence,N/a,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 10:13:35,1738653055,9/15/2015 10:12:17,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prevalence,N/A,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 10:17:09,1738654038,9/15/2015 10:16:15,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],SINGLE RESISTANT TUBERCULOSIS ISONIAZID 0.7% 22.7%,prevent,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 10:19:18,1738654521,9/15/2015 10:18:39,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[CONTRAINDICATES],[CONTRAINDICATES],3.4% to 41% for ISONIAZID,n/a,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 10:25:27,1738656200,9/15/2015 10:25:14,false,elite,1.0,30659754,USA,"","",162.250.145.204,[OTHER],[OTHER],for,N/A,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660703,9/15/2015 10:31:47,1738657596,9/15/2015 10:31:17,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],The prevalence of for,N/A,18,81,52,51,90,RO-may_prevent,820249-FS1,"The prevalence of SINGLE DRUG RESISTANT TUBERCULOSIS ranged from 3.4% to 41% for ISONIAZID 0% to 23.4% for rifampicin, 0.7% to 22.7% for streptomycin and 0% to 6.9% for ethambutol.",SINGLE DRUG RESISTANT TUBERCULOSIS,ISONIAZID
788660704,9/15/2015 12:54:47,1738707207,9/15/2015 12:54:37,false,neodev,1,30581619,USA,CA,San Jose,50.118.172.208,[NONE],[NONE],very good,very good,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 13:02:36,1738709259,9/15/2015 13:02:24,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[TREATS] [CONTRAINDICATES] [LOCATION] [NONE],"[TREATS]
[LOCATION]
[CONTRAINDICATES]
[NONE]",[SIDE_EFFECT],N/A,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 13:02:40,1738709266,9/15/2015 13:02:05,false,elite,1.0,28548715,USA,"","",38.95.108.245,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treatment Lower risk,n/a,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 13:03:42,1738709530,9/15/2015 13:03:25,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],RIFAMPIN,none,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 13:20:27,1738714207,9/15/2015 13:20:09,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],Improved adherence less toxicity with RIFAMPIN,n/a,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 13:22:18,1738714851,9/15/2015 13:20:55,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[TREATS],[TREATS],for treatment of,N/A,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 13:24:57,1738715819,9/15/2015 13:23:17,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],DRUG RESISTANT PULMONARY TUBERCULOSIS Improved adherence and less toxicity with RIFAMPIN,n/a,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 13:32:39,1738717895,9/15/2015 13:32:16,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],DRUG RESISTANT PULMONARY TUBERCULOSIS adherence less toxicity with RIFAMPIN,N/A,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 14:07:47,1738728673,9/15/2015 14:07:29,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],treatment,n/a,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 14:20:05,1738732156,9/15/2015 14:19:17,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],DRUG RESISTANT PULMONARY TUBERCULOSIS Improved adherence and less toxicity with RIFAMPIN,n/a,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 14:31:46,1738735405,9/15/2015 14:31:23,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],for treatment,N/A,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 14:41:52,1738738177,9/15/2015 14:41:30,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[NONE] [CAUSES],"[CAUSES]
[NONE]",N/A,N/A,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 14:47:41,1738739993,9/15/2015 14:47:09,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],RIFAMPIN for treatment of latent tuberculosis:,n/a,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 14:49:05,1738740372,9/15/2015 14:48:11,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[TREATS],[TREATS],Improved adherence less toxicity,N/A,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660704,9/15/2015 15:01:01,1738743749,9/15/2015 15:00:35,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],for treatment of,N/A,0,112,37,36,120,RO-may_prevent,820370-FS1,"DRUG RESISTANT PULMONARY TUBERCULOSIS  Archives of Internal Medicine  Improved adherence and less toxicity with RIFAMPIN vs isoniazid for treatment of latent tuberculosis: a retrospective study  Transmission of Mycobacterium tuberculosis through casual contact with an infectious case  Prospective validation of a prediction model for isolating inpatients with suspected pulmonary tuberculosis  Lower risk of tuberculosis in obesity  Tuberculosis in South Asians living in the United States, 1993 2004  Isoniazid monoresistant tuberculosis in the United States, 1993 to 2003  Cost effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers  Tuberculosis and substance abuse in the.",DRUG RESISTANT PULMONARY TUBERCULOSIS,RIFAMPIN
788660705,9/15/2015 09:26:38,1738639710,9/15/2015 09:26:24,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],treated with,N/A,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 09:40:23,1738644001,9/15/2015 09:39:58,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treated,N/A,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 09:47:14,1738645815,9/15/2015 09:46:39,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[TREATS],[TREATS],treated with,n/a,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 09:50:47,1738646812,9/15/2015 09:50:23,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],have been treated,N/A,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 09:55:02,1738647980,9/15/2015 09:54:49,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treated,n/a,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 10:02:11,1738649747,9/15/2015 10:01:35,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treated,N/A,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 10:02:45,1738649968,9/15/2015 10:02:36,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS],[TREATS],have been treated,N/A,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 10:06:49,1738651096,9/15/2015 10:06:34,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treated,N/A,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 10:08:46,1738651663,9/15/2015 10:08:35,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],treated,N/A,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 10:10:18,1738652096,9/15/2015 10:10:03,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],treated,N/a,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 10:14:01,1738653224,9/15/2015 10:13:36,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],treated,N/A,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 10:17:44,1738654195,9/15/2015 10:17:10,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[PREVENTS],[PREVENTS],MALARIA have been with CHLOROQUINE for decades.,treat,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 10:20:02,1738654736,9/15/2015 10:19:19,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[OTHER] [TREATS],"[TREATS]
[OTHER]",have been treated with CHLOROQUINE,n/a,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 10:25:39,1738656269,9/15/2015 10:25:29,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],treated,N/A,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660705,9/15/2015 10:34:56,1738658411,9/15/2015 10:34:44,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treated,N/A,25,56,32,31,67,RO-may_prevent,820371-FS1,Rheumatoid arthritis and MALARIA have been treated with CHLOROQUINE for decades.,MALARIA,CHLOROQUINE
788660706,9/15/2015 12:36:16,1738701992,9/15/2015 12:35:37,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],stroke,NONE,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 12:53:05,1738706835,9/15/2015 12:52:48,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[NONE],[NONE],very good,very good,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 12:59:06,1738708312,9/15/2015 12:58:43,false,elite,1.0,28548715,USA,"","",38.95.108.245,[TREATS],[TREATS],therapy,n/a,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 13:00:58,1738708788,9/15/2015 13:00:43,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[LOCATION] [PART_OF] [IS_A] [ASSOCIATED_WITH] [NONE],"[LOCATION]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]
[NONE]",[TREATS],N/A,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 13:01:20,1738708884,9/15/2015 13:01:07,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],WARFARIN,none,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 13:10:09,1738711230,9/15/2015 13:09:07,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[PREVENTS],[PREVENTS],WARFARIN for prevention of stroke in patients with ATRIAL FIBRILLATION:,n/a,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 13:10:39,1738711334,9/15/2015 13:09:45,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[PREVENTS] [OTHER],"[PREVENTS]
[OTHER]",for prevention of,N/A,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 13:17:52,1738713447,9/15/2015 13:17:35,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[PREVENTS],[PREVENTS],therapy for prevention,n/a,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 13:29:14,1738717156,9/15/2015 13:28:46,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[PREVENTS],[PREVENTS],WARFARIN therapy prevention stroke patients with ATRIAL FIBRILLATION:,N/A,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 14:05:03,1738728001,9/15/2015 14:04:47,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[PREVENTS],[PREVENTS],prevention,n/a,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 14:12:15,1738729765,9/15/2015 14:11:54,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION:,n/a,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 14:29:21,1738734841,9/15/2015 14:29:07,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[PREVENTS],[PREVENTS],therapy for prevention,N/A,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 14:39:28,1738737433,9/15/2015 14:39:16,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[NONE] [SYMPTOM],"[SYMPTOM]
[NONE]",A,A,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 14:42:30,1738738422,9/15/2015 14:41:02,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[PREVENTS],[PREVENTS],prevention,N/A,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660706,9/15/2015 14:45:31,1738739318,9/15/2015 14:42:55,false,clixsense,1,24204845,GBR,L3,Rotherham,86.162.168.250,[PREVENTS],[PREVENTS],WARFARIN stroke ATRIAL FIBRILLATION:,N/A,128,69,147,146,77,RO-may_treat,820097-FS1,2009 08 15  Percutaneous closure of the left atrial appendage versus WARFARIN therapy for prevention of stroke in patients with ATRIAL FIBRILLATION: a randomised non inferiority trial.,ATRIAL FIBRILLATION,WARFARIN
788660707,9/15/2015 10:44:52,1738660954,9/15/2015 10:44:40,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],measured three six months,n/a,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 10:45:25,1738661094,9/15/2015 10:45:14,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],measured,N/A,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 10:52:42,1738662800,9/15/2015 10:52:10,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[ASSOCIATED_WITH],[ASSOCIATED_WITH],six months after,N/A,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 10:54:20,1738663192,9/15/2015 10:53:53,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],measured,N/A,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 10:55:01,1738663328,9/15/2015 10:54:17,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[PREVENTS],[PREVENTS],inhibitor,Prevent,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 10:58:18,1738664020,9/15/2015 10:57:32,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[MANIFESTATION],[MANIFESTATION],measured three to six months after,N/a,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 11:05:04,1738665603,9/15/2015 11:04:52,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,N/A,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 11:33:23,1738678366,9/15/2015 11:31:13,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],were measured three to six months after,N/A,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 11:36:12,1738679586,9/15/2015 11:35:17,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER],[OTHER],inhibitor of measured,N/A,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 11:39:24,1738680863,9/15/2015 11:38:20,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[SIDE_EFFECT] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",fast inhibitor TISSUE PLASMINOGEN ACTIVATOR after MYOCARDIAL INFARCTION,N/A,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 11:59:25,1738689425,9/15/2015 11:58:57,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[PREVENTS],[PREVENTS],inhibitor,n/a,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 12:20:02,1738696542,9/15/2015 12:19:46,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PLASMINOGEN,NONE,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 12:20:22,1738696655,9/15/2015 12:19:29,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],measured,N/A,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 12:37:43,1738702564,9/15/2015 12:36:41,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[SIDE_EFFECT],[SIDE_EFFECT],were measured after,N/A,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660707,9/15/2015 12:41:25,1738703727,9/15/2015 12:39:52,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [LOCATION] [CONTRAINDICATES] [ASSOCIATED_WITH] [OTHER] [PART_OF] [IS_A] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[LOCATION]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[IS_A]
[PART_OF]
[OTHER]
[NONE]",none,very good,257,188,279,277,216,RO-may_treat,820131-FS1,"Coagulation factor VIII, von Willebrand factor, antithrombin, fibrinogen, plasminogen activator capacity, and inhibitors of fibrinolysis, including a recently discovered fast inhibitor of TISSUE PLASMINOGEN ACTIVATOR were measured three to six months after MYOCARDIAL INFARCTION in 116 male and 32 female patients aged less than 45 and in 136 age and sex matched random controls.",MYOCARDIAL INFARCTION,TISSUE PLASMINOGEN ACTIVATOR
788660708,9/15/2015 09:40:03,1738643957,9/15/2015 09:39:36,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],patients with,N/A,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 09:57:08,1738648460,9/15/2015 09:56:41,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Aspirin must be combined with and,n/a,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:02:58,1738650028,9/15/2015 10:02:40,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:07:53,1738651370,9/15/2015 10:07:15,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],must be combined with,N/A,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:08:55,1738651720,9/15/2015 10:05:56,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and with,N/A,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:12:00,1738652642,9/15/2015 10:11:35,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[SIDE_EFFECT] [SYMPTOM] [MANIFESTATION] [TREATS],"[TREATS]
[SYMPTOM]
[MANIFESTATION]
[SIDE_EFFECT]",must be combined patients with unstable angina.,N/A,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:18:20,1738654326,9/15/2015 10:18:05,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],combined,N/A,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:20:33,1738654833,9/15/2015 10:20:02,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[OTHER],[OTHER],and with,N/A,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:25:22,1738656185,9/15/2015 10:23:25,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[NONE],[NONE],N/A,one is a disease one is a drug but the drug mentioned is for treatment of another disease.,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:25:31,1738656229,9/15/2015 10:25:09,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[ASSOCIATED_WITH],[ASSOCIATED_WITH],combined,N/a,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:30:11,1738657278,9/15/2015 10:29:54,false,elite,1.0,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:32:21,1738657757,9/15/2015 10:31:26,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[IS_A],[IS_A],and with,N/A,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:32:44,1738657895,9/15/2015 10:32:18,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],MYOCARDIAL INFARCTION HEPARIN,true,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:35:09,1738658466,9/15/2015 10:34:58,false,elite,1.0,30659677,USA,"","",162.252.172.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660708,9/15/2015 10:35:50,1738658576,9/15/2015 10:35:19,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MYOCARDIAL INFARCTION HEPARIN,n/a,68,99,89,88,106,RO-may_treat,820133-FS1,Aspirin must be combined with a thrombolytic agent in patients with MYOCARDIAL INFARCTION and with HEPARIN in patients with unstable angina.,MYOCARDIAL INFARCTION,HEPARIN
788660709,9/15/2015 12:28:15,1738699138,9/15/2015 12:27:46,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 12:31:24,1738700232,9/15/2015 12:30:24,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],Herpes,NONE,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 12:51:31,1738706464,9/15/2015 12:51:15,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",very good,very good,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 12:56:10,1738707569,9/15/2015 12:55:37,false,elite,1.0,28548715,USA,"","",38.95.108.245,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",Association Risk,n/a,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 12:58:54,1738708248,9/15/2015 12:58:39,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[PREVENTS] [MANIFESTATION] [IS_A] [NONE],"[PREVENTS]
[MANIFESTATION]
[IS_A]
[NONE]",[LOCATION],N/A,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 12:59:31,1738708414,9/15/2015 12:58:39,false,neodev,1.0,34081836,USA,CA,San Jose,173.245.65.34,[SIDE_EFFECT],[SIDE_EFFECT],The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER,The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 12:59:38,1738708432,9/15/2015 12:59:23,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],FAMCICLOVIR,none,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 12:59:40,1738708435,9/15/2015 12:58:35,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],FAMCICLOVIR in treatment of HERPES ZOSTER,n/a,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 13:02:52,1738709312,9/15/2015 13:01:48,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[TREATS],[TREATS],treatment of,N/A,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 13:15:06,1738712535,9/15/2015 13:14:42,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],Managing,n/a,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 13:25:41,1738716098,9/15/2015 13:25:10,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],FAMCICLOVIR treatment of HERPES ZOSTER,N/A,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 13:38:00,1738721460,9/15/2015 13:37:22,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[TREATS],[TREATS],treatment,n/a,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 13:53:41,1738725211,9/15/2015 13:53:04,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],FAMCICLOVIR block treatment HERPES ZOSTER,n/a,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 14:02:44,1738727435,9/15/2015 14:02:17,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],treatment,N/A,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660709,9/15/2015 14:29:07,1738734745,9/15/2015 14:28:49,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],in the treatment of,N/A,293,242,306,305,253,RO-may_prevent,820256-FS1,Herpes  Managing herpes zoster in immunocompromised patients  Journal of the American Medical Association  Risk of herpes zoster in patients with rheumatoid arthritis treated with anti TNF alpha agents  Journal of Dermatology  The effects of FAMCICLOVIR and epidural block in the treatment of HERPES ZOSTER  Journal of Pain.,HERPES ZOSTER,FAMCICLOVIR
788660710,9/15/2015 09:27:12,1738639837,9/15/2015 09:26:39,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],remove endogenous or exogenous toxins,N/A,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 09:41:36,1738644337,9/15/2015 09:40:24,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],remove,N/A,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 09:47:47,1738645961,9/15/2015 09:47:15,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[OTHER],[OTHER],to remove,n/a,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 09:51:39,1738647043,9/15/2015 09:50:50,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],to remove endogenous or exogenous toxins,N/A,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 09:55:34,1738648086,9/15/2015 09:55:02,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],to remove,n/a,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 10:03:07,1738650075,9/15/2015 10:02:47,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS],[TREATS],remove endogenous exogenous toxins,N/A,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 10:03:23,1738650150,9/15/2015 10:02:12,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA,N/A,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 10:07:16,1738651225,9/15/2015 10:06:50,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],to remove,N/A,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 10:09:09,1738651755,9/15/2015 10:08:48,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],remove,N/A,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 10:12:30,1738652785,9/15/2015 10:10:19,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],remove,N/a,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 10:13:57,1738653201,9/15/2015 10:13:34,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],remove endogenous or exogenous toxins,n/a,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 10:15:14,1738653515,9/15/2015 10:14:02,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],remove endogenous or exogenous toxins in,N/A,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 10:18:17,1738654308,9/15/2015 10:17:45,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ACTIVATED CHARCOAL UREMIA,treat,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 10:25:53,1738656322,9/15/2015 10:25:41,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],remove,N/A,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660710,9/15/2015 10:32:06,1738657697,9/15/2015 10:31:48,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],ACTIVATED CHARCOAL to remove in UREMIA,N/A,111,48,117,116,66,RO-may_treat,820015-FS1,"Hemoperfusion  Hemoperfusion through columns of ACTIVATED CHARCOAL to remove endogenous or exogenous toxins in UREMIA hepatic failure, or acute toxicity associated with overdose of certain drugs.",UREMIA,ACTIVATED CHARCOAL
788660711,9/15/2015 12:06:30,1738691438,9/15/2015 12:06:17,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],treatment,n/a,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 12:26:47,1738698637,9/15/2015 12:26:25,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 12:29:03,1738699354,9/15/2015 12:27:32,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],PEPTIC ULCER DISEASE,NONE,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 12:50:46,1738706236,9/15/2015 12:50:34,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",very good,very good,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 12:54:02,1738706996,9/15/2015 12:53:39,false,elite,1.0,28548715,USA,"","",38.95.108.245,[TREATS],[TREATS],treatment,n/a,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 12:54:27,1738707074,9/15/2015 12:53:43,false,neodev,1.0,34081836,USA,CA,San Jose,173.245.65.34,[TREATS],[TREATS],been used in fixed combination with CLIDINIUM,Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 12:55:23,1738707366,9/15/2015 12:54:21,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[TREATS],[TREATS],adjunct in the treatment,N/A,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 12:55:42,1738707437,9/15/2015 12:54:31,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],Has been used fixed combination CLIDINIUM in the treatment of PEPTIC ULCER DISEASE,n/a,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 12:57:46,1738707961,9/15/2015 12:56:52,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[PREVENTS] [CAUSES] [ASSOCIATED_WITH] [OTHER] [NONE],"[PREVENTS]
[CAUSES]
[ASSOCIATED_WITH]
[OTHER]
[NONE]",[PART_OF],N/A,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 12:58:46,1738708191,9/15/2015 12:58:03,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PEPTIC ULCER DISEASE,none,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 13:13:59,1738712247,9/15/2015 13:12:44,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],treatment of,n/a,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 13:23:48,1738715385,9/15/2015 13:22:57,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],CLIDINIUM bromide treatment of PEPTIC ULCER DISEASE,NONE,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 13:36:40,1738720022,9/15/2015 13:35:54,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[OTHER],[OTHER],combination,N/A,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 13:39:36,1738722006,9/15/2015 13:38:30,false,points4rewards,1,28755767,USA,VA,Chester,68.57.118.32,[TREATS],[TREATS],treatment,N/A,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660711,9/15/2015 13:51:44,1738724761,9/15/2015 13:51:10,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],treatment PEPTIC ULCER,n/a,180,128,200,199,137,RO-may_treat,820016-FS1,"a ,   b ,   c  Peptic Ulcer Disease, Irritable Bowel Syndrome, and Acute Enterocolitis  Has been used in fixed combination with CLIDINIUM bromide as an adjunct in the treatment of PEPTIC ULCER DISEASE functional disturbances of GI motility (e.g., irritable bowel syndrome), and acute enterocolitis.",PEPTIC ULCER DISEASE,CLIDINIUM
788660712,9/15/2015 09:21:02,1738638373,9/15/2015 09:19:39,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],treatment of,N/A,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 09:22:49,1738638817,9/15/2015 09:21:05,false,neodev,1,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[NONE],[NONE],N/a,"The correct opti""treated by"" but this is not available.",215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 09:26:28,1738639676,9/15/2015 09:24:31,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 09:38:40,1738643458,9/15/2015 09:38:15,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],in the treatment of,N/A,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 09:42:10,1738644462,9/15/2015 09:40:49,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[OTHER],[OTHER],in the treatment of,n/a,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 09:50:14,1738646590,9/15/2015 09:49:30,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treatment,none,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 09:51:37,1738647038,9/15/2015 09:49:42,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the treatment,NA,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 09:57:46,1738648637,9/15/2015 09:56:19,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treatment,N/A,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 09:57:47,1738648649,9/15/2015 09:57:30,false,neodev,1,18703384,GBR,T5,Aberdeen,151.231.237.211,[OTHER],[OTHER],treatment of,N/A,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 09:57:57,1738648686,9/15/2015 09:55:30,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS],[TREATS],treatment,N/A,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 09:59:54,1738649149,9/15/2015 09:59:17,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],treatment,N/a,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 10:02:09,1738649746,9/15/2015 10:00:45,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],treatment,N/A,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 10:03:48,1738650298,9/15/2015 10:02:10,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],treatment of,N/A,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 10:06:49,1738651087,9/15/2015 10:04:11,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND DUODENAL ULCER,treatment,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660712,9/15/2015 10:12:25,1738652769,9/15/2015 10:10:49,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],in the treatment of,n/a,215,145,229,228,194,RO-may_prevent,820259-FS1,"A multicenter, double blind, randomized, controlled study was conducted in 234 duodenal ulcer patients to compare the efficacy and safety of the H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE in the treatment of DUODENAL ULCER",DUODENAL ULCER,H2 RECEPTOR ANTAGONISTS FAMOTIDINE AND RANITIDINE
788660713,9/15/2015 10:37:47,1738659139,9/15/2015 10:37:33,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],developed,N/A,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 10:39:15,1738659540,9/15/2015 10:38:50,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 10:41:22,1738660144,9/15/2015 10:41:00,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],subsequently developed,n/a,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 10:43:20,1738660644,9/15/2015 10:43:05,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],developed,N/A,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 10:44:34,1738660887,9/15/2015 10:43:31,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[OTHER],[OTHER],not associated,N/A,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 10:47:37,1738661665,9/15/2015 10:46:03,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,Assosiate,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 10:51:53,1738662663,9/15/2015 10:51:34,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],developed,N/A,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 10:52:02,1738662679,9/15/2015 10:51:28,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[NONE],[NONE],N/a,Not related in the text,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 11:02:42,1738665007,9/15/2015 11:02:22,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],developed,N/A,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 11:13:08,1738667743,9/15/2015 11:11:39,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",subsequently developed,N/A,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 11:21:14,1738671763,9/15/2015 11:20:07,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[ASSOCIATED_WITH],[ASSOCIATED_WITH],not associated with AZIDOTHYMIDINE who developed ACQUIRED IMMUNODEFICIENCY SYNDROME,N/a,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 11:26:56,1738675129,9/15/2015 11:24:52,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[PREVENTS],[PREVENTS],developed,N/A,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 11:30:10,1738676815,9/15/2015 11:29:19,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],not associated with AZIDOTHYMIDINE developed ACQUIRED IMMUNODEFICIENCY,N/A,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 11:54:11,1738687741,9/15/2015 11:53:25,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[CAUSES],[CAUSES],developed,n/a,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660713,9/15/2015 12:13:02,1738693838,9/15/2015 12:10:34,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],AZIDOTHYMIDINE,none,108,66,143,141,80,RO-may_treat,820139-FS1,"Three other cases of porphyria cutanea tarda, not associated with AZIDOTHYMIDINE who subsequently developed ACQUIRED IMMUNODEFICIENCY SYNDROME have recently been described.",ACQUIRED IMMUNODEFICIENCY SYNDROME,AZIDOTHYMIDINE
788660714,9/15/2015 12:54:04,1738707008,9/15/2015 12:53:50,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[NONE] [TREATS],"[TREATS]
[NONE]",very good,very good,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 13:00:58,1738708793,9/15/2015 13:00:39,false,elite,1.0,28548715,USA,"","",38.95.108.245,[PREVENTS],[PREVENTS],prevent,n/a,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 13:01:54,1738709060,9/15/2015 13:01:45,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [MANIFESTATION] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]
[MANIFESTATION]
[NONE]",[SIDE_EFFECT],N/A,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 13:02:40,1738709262,9/15/2015 13:02:21,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],DIABETES TYPE I AND II,none,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 13:16:15,1738712885,9/15/2015 13:14:40,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[PREVENTS] [SIDE_EFFECT],"[PREVENTS]
[SIDE_EFFECT]",Hypersecretion of insulin increases chance of DIABETES TYPE I AND II INSULIN helps prevent diabetes.,n/a,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 13:18:31,1738713627,9/15/2015 13:16:42,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",inhibiting helps prevent,N/A,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 13:19:18,1738713883,9/15/2015 13:18:56,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],inhibiting INSULIN secretion helps prevent diabetes.,n/a,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 13:31:21,1738717599,9/15/2015 13:30:48,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[PREVENTS],[PREVENTS],DIABETES TYPE I AND II INSULIN secretion prevent,N/A,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 14:06:46,1738728452,9/15/2015 14:06:28,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[PREVENTS],[PREVENTS],prevent,n/a,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 14:16:08,1738730945,9/15/2015 14:15:30,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],inhibiting INSULIN secretion helps prevent diabetes.,n/a,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 14:30:44,1738735188,9/15/2015 14:30:29,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],while inhibiting,N/A,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 14:40:48,1738737758,9/15/2015 14:40:29,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",A,A,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 14:45:44,1738739384,9/15/2015 14:45:21,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[CAUSES],[CAUSES],increases the chance of,n/a,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 14:46:13,1738739503,9/15/2015 14:45:18,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[ASSOCIATED_WITH],[ASSOCIATED_WITH],insulin increases inhibiting prevent,N/A,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660714,9/15/2015 14:49:59,1738740608,9/15/2015 14:48:32,false,clixsense,1.0,24204845,GBR,L3,Rotherham,86.162.168.250,[PREVENTS],[PREVENTS],DIABETES TYPE I AND II inhibiting INSULIN prevent diabetes.,N/A,67,107,82,88,114,RO-may_treat,820140-FS1,Hypersecretion of insulin increases the chance of the incidence of DIABETES TYPE I AND II while inhibiting INSULIN secretion helps prevent diabetes.,DIABETES TYPE I AND II,INSULIN
788660715,9/15/2015 09:33:05,1738641360,9/15/2015 09:32:40,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],use of,N/A,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 09:55:10,1738648034,9/15/2015 09:54:47,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for,n/a,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:01:10,1738649448,9/15/2015 10:00:49,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],use of,n/a,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:01:37,1738649608,9/15/2015 10:00:49,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],for,N/A,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:03:25,1738650154,9/15/2015 10:02:30,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],the use of in patients with comorbid mental illness.,N/A,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:09:40,1738651899,9/15/2015 10:09:12,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS],[TREATS],the use of for,N/A,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:16:19,1738653856,9/15/2015 10:15:56,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],use,N/A,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:17:23,1738654079,9/15/2015 10:17:01,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],use for,N/A,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:18:55,1738654431,9/15/2015 10:17:01,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],about the use of DISULFIRAM and naltrexone for ALCOHOLISM,N/A,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:21:58,1738655216,9/15/2015 10:21:34,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[ASSOCIATED_WITH],[ASSOCIATED_WITH],use,N/a,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:27:32,1738656605,9/15/2015 10:26:47,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],use of for,N/A,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:28:35,1738656857,9/15/2015 10:28:01,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],This article the DISULFIRAM ALCOHOLISM,yes,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:28:52,1738656913,9/15/2015 10:28:40,false,elite,1.0,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:33:48,1738658109,9/15/2015 10:33:37,false,elite,1.0,30659677,USA,"","",162.252.172.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660715,9/15/2015 10:34:52,1738658397,9/15/2015 10:33:52,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],use,N/A,96,66,106,105,76,RO-may_prevent,820383-FS1,This article outlines a review of the literature about the use of DISULFIRAM and naltrexone for ALCOHOLISM and in patients with comorbid mental illness.,ALCOHOLISM,DISULFIRAM
788660716,9/15/2015 10:45:21,1738661088,9/15/2015 10:45:12,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],treatment,n/a,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 10:45:53,1738661224,9/15/2015 10:45:41,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 10:54:23,1738663197,9/15/2015 10:53:58,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],treatment,N/A,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 10:54:48,1738663288,9/15/2015 10:54:36,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 10:56:46,1738663765,9/15/2015 10:56:11,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],therapy,Tteat,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 10:58:57,1738664209,9/15/2015 10:58:43,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],treatment of,N/a,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 11:05:49,1738665746,9/15/2015 11:05:28,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],followed:,N/A,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 11:37:06,1738680010,9/15/2015 11:36:38,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment of,N/A,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 11:37:31,1738680163,9/15/2015 11:37:13,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatment of,N/A,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 11:40:39,1738681441,9/15/2015 11:40:03,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES,N/A,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 12:00:21,1738689705,9/15/2015 11:59:49,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],treatment,n/a,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 12:21:14,1738696909,9/15/2015 12:20:37,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[CAUSES],[CAUSES],AMPHOTERICIN,NONE,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 12:21:25,1738696935,9/15/2015 12:20:57,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 12:39:51,1738703296,9/15/2015 12:38:36,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [LOCATION] [SYMPTOM] [CONTRAINDICATES] [SIDE_EFFECT] [PART_OF] [MANIFESTATION] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[LOCATION]
[SYMPTOM]
[MANIFESTATION]
[CONTRAINDICATES]
[SIDE_EFFECT]
[PART_OF]
[NONE]",good,very good,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660716,9/15/2015 12:46:22,1738705144,9/15/2015 12:45:45,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],AMPHOTERICIN B treatment SEVERE SYSTEMIC MYCOSES,n/a,242,206,265,264,220,RO-may_prevent,820384-FS1,"Two distinct eras of rapid progress in antifungal therapy followed: first, in the 1950's came the introduction of the polyenes, nystatin and pimaricin for cutaneous, vaginal and intestinal candidiasis, and AMPHOTERICIN B for the treatment of SEVERE SYSTEMIC MYCOSES",SEVERE SYSTEMIC MYCOSES,AMPHOTERICIN B
788660717,9/15/2015 09:23:41,1738639013,9/15/2015 09:23:06,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[CAUSES],[CAUSES],resulted in increased,N/A,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 09:34:13,1738641759,9/15/2015 09:31:21,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[CAUSES],[CAUSES],resulted,N/A,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 09:44:20,1738645151,9/15/2015 09:43:50,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],resulted in,n/a,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 09:44:28,1738645184,9/15/2015 09:43:08,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[CONTRAINDICATES],[CONTRAINDICATES],resulted in increased PAIN,N/A,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 09:52:16,1738647199,9/15/2015 09:51:43,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[CAUSES],[CAUSES],resulted in,n/a,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 09:55:50,1738648173,9/15/2015 09:55:23,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],resulted in increased PAIN,N/A,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 09:59:48,1738649116,9/15/2015 09:59:31,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[CAUSES],[CAUSES],increased,N/A,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 10:02:41,1738649897,9/15/2015 10:02:23,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[CAUSES],[CAUSES],resulted in,N/A,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 10:05:37,1738650765,9/15/2015 10:04:51,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[SYMPTOM],[SYMPTOM],resulted,N/a,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 10:05:48,1738650818,9/15/2015 10:05:25,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],increased,N/A,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 10:07:33,1738651291,9/15/2015 10:06:51,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],addition of,N/A,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 10:13:47,1738653117,9/15/2015 10:12:53,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],the addition LIDOCAINE to the contrast PAIN,treat,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 10:15:24,1738653541,9/15/2015 10:14:50,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[CAUSES],[CAUSES],addition LIDOCAINE resulted in PAIN,n/a,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 10:24:17,1738655895,9/15/2015 10:24:05,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CONTRAINDICATES],[CONTRAINDICATES],contrast,N/A,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660717,9/15/2015 10:26:22,1738656409,9/15/2015 10:25:03,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[SIDE_EFFECT],[SIDE_EFFECT],addition,N/A,132,77,136,135,86,RO-may_prevent,820264-FS1,"In patients premedicated with 5  10 mg Valium intravenously, the addition of LIDOCAINE to the contrast medium resulted in increased PAIN in half the patients and no difference in the others.",PAIN,LIDOCAINE
788660718,9/15/2015 09:27:47,1738639971,9/15/2015 09:27:13,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],Inhibits,N/A,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 09:44:34,1738645233,9/15/2015 09:41:37,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[NONE],[NONE],N/A,Drug is used for INSULIN and LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 09:48:33,1738646117,9/15/2015 09:47:49,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[OTHER] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[OTHER]",Oral hypoglycemic agents Inhibits,n/a,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 09:52:44,1738647348,9/15/2015 09:51:43,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]",Possible dosage adjustment,N/A,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 09:55:57,1738648227,9/15/2015 09:55:35,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[PREVENTS],[PREVENTS],Inhibits,n/a,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 10:03:37,1738650219,9/15/2015 10:03:08,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",Possible dosage adjustment,N/A,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 10:04:28,1738650440,9/15/2015 10:03:25,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Possible dosage adjustment,N/A,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 10:08:47,1738651670,9/15/2015 10:07:17,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[CAUSES],[CAUSES],Inhibits,N/A,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 10:09:31,1738651820,9/15/2015 10:09:10,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],decreased,N/A,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 10:13:22,1738652988,9/15/2015 10:12:32,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[ASSOCIATED_WITH],[ASSOCIATED_WITH],dosage,N/a,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 10:15:46,1738653674,9/15/2015 10:15:15,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[PREVENTS],[PREVENTS],possible alterations,N/A,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 10:18:52,1738654411,9/15/2015 10:18:18,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[PREVENTS],[PREVENTS],LEVELS (HYPOGLYCEMIA HYPERGLYCEMIA) quinidine clearance,cure,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 10:21:05,1738654971,9/15/2015 10:20:03,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[MANIFESTATION],[MANIFESTATION],alterations of plasma glucose,n/a,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 10:26:09,1738656388,9/15/2015 10:25:55,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SIDE_EFFECT],[SIDE_EFFECT],alterations,N/A,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660718,9/15/2015 10:32:55,1738657924,9/15/2015 10:31:51,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],Inhibits,N/A,187,139,224,224,146,RO-may_treat,820024-FS1,"plasma glucose levels (hypoglycemia or hyperglycemia) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Oral hypoglycemic agents Inhibits INSULIN; possible alterations of plasma glucose LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA) [ 1 , 26 ] Possible dosage adjustment [ 1 , 26 ]   Quinidine Possible decreased quinidine clearance [ 1 , 26 ] Use concomitantly with caution [ 1 , 26.",LEVELS (HYPOGLYCEMIA OR HYPERGLYCEMIA),INSULIN
788660719,9/15/2015 09:23:05,1738638892,9/15/2015 09:22:40,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[CAUSES],[CAUSES],attacks,N/A,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 09:31:20,1738640860,9/15/2015 09:29:51,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[PREVENTS],[PREVENTS],consumption,N/A,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 09:43:05,1738644725,9/15/2015 09:41:24,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[PREVENTS],[PREVENTS],reduced significantly the number and intensity,N/A,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 09:43:48,1738644993,9/15/2015 09:43:26,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[OTHER],[OTHER],and,n/a,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 09:51:42,1738647044,9/15/2015 09:51:11,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[PART_OF],[PART_OF],and,n/a,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 09:55:22,1738648059,9/15/2015 09:54:04,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN,N/A,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 09:59:30,1738649015,9/15/2015 09:58:57,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 10:02:22,1738649812,9/15/2015 09:59:53,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[OTHER],[OTHER],and the consumption of,N/A,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 10:04:50,1738650531,9/15/2015 10:03:47,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[SYMPTOM],[SYMPTOM],attacks,N/a,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 10:05:24,1738650687,9/15/2015 10:04:51,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[PREVENTS],[PREVENTS],reduced,N/A,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 10:06:50,1738651092,9/15/2015 10:05:46,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[CAUSES],[CAUSES],consumption of,N/A,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 10:12:51,1738652869,9/15/2015 10:11:27,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],the number and intensity of ANGINA PECTORIS attacks NITROGLYCERIN capsules.,treat,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 10:14:50,1738653413,9/15/2015 10:13:58,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS] [SIDE_EFFECT],"[TREATS]
[SIDE_EFFECT]",consumption of,n/a,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 10:24:03,1738655824,9/15/2015 10:23:51,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CAUSES],[CAUSES],attacks,N/A,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660719,9/15/2015 10:25:02,1738656107,9/15/2015 10:23:21,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[PREVENTS],[PREVENTS],reduced,N/A,74,121,89,88,134,RO-may_prevent,820266-FS1,Pindolol reduced in both groups significantly the number and intensity of ANGINA PECTORIS attacks and the consumption of NITROGLYCERIN capsules.,ANGINA PECTORIS,NITROGLYCERIN
788660720,9/15/2015 10:44:39,1738660915,9/15/2015 10:43:19,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",justified advantage,n/a,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 10:45:12,1738661056,9/15/2015 10:45:00,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[PREVENTS],[PREVENTS],advantage,N/A,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 10:52:09,1738662682,9/15/2015 10:51:39,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],screening,N/A,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 10:53:52,1738663080,9/15/2015 10:53:39,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detection,N/A,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 10:54:16,1738663177,9/15/2015 10:53:06,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],advantage,Treat,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 10:57:31,1738663874,9/15/2015 10:56:41,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[OTHER],[OTHER],is a justified advantage of the,N/a,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 11:04:50,1738665501,9/15/2015 11:04:38,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detection,N/A,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 11:31:10,1738677488,9/15/2015 11:29:53,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"screening strategy,",N/A,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 11:35:14,1738679109,9/15/2015 11:34:42,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detection of,N/A,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 11:38:19,1738680396,9/15/2015 11:37:06,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[SYMPTOM],[SYMPTOM],determine whether the detection,N/A,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 11:58:56,1738689296,9/15/2015 11:58:01,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],advantage,n/a,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 12:19:27,1738696317,9/15/2015 12:18:36,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],determine,N/A,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 12:19:44,1738696462,9/15/2015 12:18:43,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],PRIMARY THYROXINE,NONE,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 12:36:40,1738702164,9/15/2015 12:33:53,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detection of,N/A,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660720,9/15/2015 12:37:03,1738702295,9/15/2015 12:35:10,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[ASSOCIATED_WITH] [PREVENTS] [SYMPTOM] [IS_A] [NONE],"[PREVENTS]
[SYMPTOM]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",good,very good,138,199,166,165,242,RO-may_prevent,820387-FS1,"We examined the results of the Northwest Regional Screening Program (NWRSP) over its first 10 years to determine whether the detection of HYPOPITUITARY HYPOTHYROIDISM is a justified advantage of the PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID stimulating hormone (TSH) screening strategy, and to determine whether all such infants will be detected by this screening approach.",HYPOPITUITARY HYPOTHYROIDISM,PRIMARY THYROXINE (T4) SUPPLEMENTAL THYROID
788660721,9/15/2015 10:30:39,1738657403,9/15/2015 10:30:26,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CAUSES],[CAUSES],target,N/A,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 10:35:38,1738658550,9/15/2015 10:35:25,false,elite,1.0,30659677,USA,"","",162.252.172.126,[LOCATION],[LOCATION],in,N/A,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 10:36:07,1738658643,9/15/2015 10:35:40,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],target of ISONIAZID in the,N/A,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 10:37:39,1738659110,9/15/2015 10:36:12,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],developoment new drugs,Drug,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 10:38:20,1738659271,9/15/2015 10:37:16,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],identification,N/A,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 10:38:25,1738659283,9/15/2015 10:38:07,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the,n/a,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 10:41:10,1738660085,9/15/2015 10:41:00,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[LOCATION],[LOCATION],in,N/A,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 10:47:34,1738661659,9/15/2015 10:47:07,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[SYMPTOM],[SYMPTOM],in the,N/a,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 10:49:33,1738662090,9/15/2015 10:49:19,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[LOCATION],[LOCATION],in,N/A,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 10:58:30,1738664054,9/15/2015 10:57:39,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[PART_OF],[PART_OF],in the,N/A,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 10:59:27,1738664304,9/15/2015 10:59:14,false,elite,1.0,30659615,USA,"","",162.250.145.234,[LOCATION],[LOCATION],in,N/A,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 11:14:54,1738668542,9/15/2015 11:14:06,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[ASSOCIATED_WITH],[ASSOCIATED_WITH],identification of ISONIAZID in MYCOBACTERIAL TUBERCULOSIS PATHOGEN,N/a,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 11:16:21,1738669179,9/15/2015 11:14:23,false,fusioncash,1.0,21457135,USA,FL,Orlando,71.47.115.162,[TREATS],[TREATS],opens the way for the developoment of new drugs,N/A,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 11:17:48,1738669852,9/15/2015 11:16:11,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],target of in,N/A,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660721,9/15/2015 11:22:31,1738672546,9/15/2015 11:21:39,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[LOCATION],[LOCATION],ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN,N/A,53,36,79,87,45,RO-may_prevent,820267-FS1,The identification of the target of ISONIAZID in the MYCOBACTERIAL TUBERCULOSIS PATHOGEN opens the way for the developoment of new drugs and diagnostic tests to combat drug resistant pathogen strains.,MYCOBACTERIAL TUBERCULOSIS PATHOGEN,ISONIAZID
788660722,9/15/2015 10:30:25,1738657348,9/15/2015 10:30:12,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],reduced,N/A,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 10:35:24,1738658497,9/15/2015 10:35:11,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],reduced,N/A,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 10:35:39,1738658554,9/15/2015 10:35:25,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],PAIN was markedly reduced by LIGNOCAINE,N/A,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 10:36:11,1738658678,9/15/2015 10:35:27,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],markedly,Treat,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 10:37:15,1738658997,9/15/2015 10:36:17,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[PREVENTS],[PREVENTS],reduced,N/A,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 10:38:06,1738659217,9/15/2015 10:35:51,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],markedly reduced,n/a,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 10:40:58,1738660066,9/15/2015 10:40:24,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],reduced,N/A,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 10:47:06,1738661549,9/15/2015 10:46:25,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],reduced,N/a,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 10:49:19,1738662008,9/15/2015 10:49:03,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],reduced,N/A,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 10:57:36,1738663891,9/15/2015 10:56:13,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[PREVENTS],[PREVENTS],reduced by,N/A,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 10:59:13,1738664259,9/15/2015 10:58:46,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],reduced,N/A,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 11:14:05,1738668189,9/15/2015 11:13:33,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],PAIN was reduced by LIGNOCAINE,N/a,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 11:14:23,1738668323,9/15/2015 11:13:00,false,fusioncash,1.0,21457135,USA,FL,Orlando,71.47.115.162,[TREATS],[TREATS],markedly reduced,I did not select none in Step 1.,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 11:16:10,1738669046,9/15/2015 11:14:08,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],reduced by,N/A,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660722,9/15/2015 11:21:38,1738672038,9/15/2015 11:20:03,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[SYMPTOM],[SYMPTOM],markedly reduced,pain is reduced,83,112,87,86,122,RO-may_prevent,820389-FS1,"When the contrast medium was injected, first without and then with lignocaine, the PAIN was markedly reduced by LIGNOCAINE",PAIN,LIGNOCAINE
788660723,9/15/2015 10:37:32,1738659079,9/15/2015 10:37:20,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treatment,N/A,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 10:38:48,1738659403,9/15/2015 10:38:34,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],is effective for treatment,N/A,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 10:40:58,1738660058,9/15/2015 10:40:34,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],effective for treatment,n/a,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 10:43:03,1738660578,9/15/2015 10:42:51,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 10:43:30,1738660663,9/15/2015 10:43:13,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],effective for treatment,N/A,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 10:46:01,1738661274,9/15/2015 10:45:14,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[SIDE_EFFECT],[SIDE_EFFECT],effective,Dide effict,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 10:51:26,1738662545,9/15/2015 10:51:10,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],for treatment,N/a,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 10:51:33,1738662576,9/15/2015 10:51:17,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 11:02:20,1738664955,9/15/2015 11:02:06,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 11:11:34,1738667143,9/15/2015 11:09:58,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment of,N/A,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 11:20:06,1738671113,9/15/2015 11:19:51,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],ZAFIRLUKAST treatment of BRONCHIAL ASTHMA,N/a,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 11:24:50,1738673929,9/15/2015 11:24:25,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],effective treatment,N/A,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 11:29:19,1738676444,9/15/2015 11:28:30,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],ZAFIRLUKAST effective treatment BRONCHIAL ASTHMA,N/A,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 11:53:24,1738687347,9/15/2015 11:52:41,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],treatment,n/a,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660723,9/15/2015 12:10:54,1738692870,9/15/2015 12:10:32,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,52,10,68,67,21,RO-may_prevent,820301-FS1,"As above, ZAFIRLUKAST is effective for treatment of BRONCHIAL ASTHMA which is attributed to its peptide leukotriene antagonistic action.",BRONCHIAL ASTHMA,ZAFIRLUKAST
788660724,9/15/2015 09:28:58,1738640249,9/15/2015 09:28:33,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],combination with,N/A,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 09:47:05,1738645779,9/15/2015 09:46:31,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],Management,N/A,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 09:50:00,1738646548,9/15/2015 09:49:28,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Management with,n/a,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 09:54:25,1738647807,9/15/2015 09:53:46,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],Management (alone or in combination with,N/A,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 09:56:53,1738648410,9/15/2015 09:56:31,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 10:04:50,1738650532,9/15/2015 10:04:36,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS],[TREATS],Management,N/A,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 10:06:16,1738650929,9/15/2015 10:05:38,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 10:10:05,1738652015,9/15/2015 10:09:32,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in combination with,N/A,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 10:11:32,1738652516,9/15/2015 10:11:02,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],combination,N/A,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 10:17:34,1738654145,9/15/2015 10:16:41,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 10:17:43,1738654192,9/15/2015 10:17:20,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],Management,N/a,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 10:19:58,1738654709,9/15/2015 10:19:36,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[PREVENTS],[PREVENTS],BIPOLAR Management DIVALPROEX SODIUM,cure,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 10:22:26,1738655335,9/15/2015 10:22:02,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],Management with DIVALPROEX SODIUM,n/a,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 10:26:37,1738656439,9/15/2015 10:26:23,false,elite,1.0,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],combination,N/A,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660724,9/15/2015 10:32:24,1738657762,9/15/2015 10:32:08,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],BIPOLAR DISORDER Management with,N/A,61,131,77,76,148,RO-may_treat,820027-FS1,"1 ,   2 ,   3 ,   4 ,   5 ,   6 ,   18 ,   22 ,   23 ,   26  BIPOLAR DISORDER  Management (alone or in combination with lithium or DIVALPROEX SODIUM of acute manic episodes associated with bipolar I disorder.",BIPOLAR DISORDER,DIVALPROEX SODIUM
788660725,9/15/2015 09:24:12,1738639089,9/15/2015 09:23:42,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[PREVENTS],[PREVENTS],reduces,N/A,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 09:36:09,1738642509,9/15/2015 09:34:14,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],requirement,N/A,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 09:44:45,1738645254,9/15/2015 09:44:22,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],requirement in patients with,n/a,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 09:46:12,1738645569,9/15/2015 09:44:32,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",reduces requirement in patients,N/A,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 09:52:51,1738647350,9/15/2015 09:52:17,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[SYMPTOM],[SYMPTOM],in,n/a,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 09:57:00,1738648425,9/15/2015 09:55:53,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE,N/A,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 10:00:16,1738649228,9/15/2015 09:59:49,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",reduces,N/A,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 10:03:47,1738650285,9/15/2015 10:02:42,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],requirement,N/A,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 10:06:09,1738650904,9/15/2015 10:05:49,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],reduces,N/A,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 10:06:19,1738650950,9/15/2015 10:05:38,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],requirement,N/a,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 10:09:46,1738651922,9/15/2015 10:07:35,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[OTHER],[OTHER],reduces requirement,N/A,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 10:14:22,1738653345,9/15/2015 10:13:48,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],Tolcapone improves motor function LEVODOPA PARKINSON'S DISEASE,treat,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 10:16:10,1738653796,9/15/2015 10:15:25,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS] [SIDE_EFFECT],"[TREATS]
[SIDE_EFFECT]",reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE,n/a,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 10:24:31,1738655955,9/15/2015 10:24:19,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],reduces,N/A,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660725,9/15/2015 10:30:43,1738657417,9/15/2015 10:29:48,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],reduces LEVODOPA requirement,N/A,130,92,149,148,100,RO-may_treat,820029-FS1,"Kurth MC, Adler CH, St Hilaire M et al et al. Tolcapone improves motor function and reduces LEVODOPA requirement in patients with PARKINSON'S DISEASE experiencing motor fluctuations: a multicenter, double blind, randomized, placebo controlled trial.",PARKINSON'S DISEASE,LEVODOPA
788660726,9/15/2015 12:54:21,1738707053,9/15/2015 12:54:05,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[NONE] [TREATS],"[TREATS]
[NONE]",very good,very good,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 13:01:37,1738708936,9/15/2015 13:00:59,false,elite,1.0,28548715,USA,"","",38.95.108.245,[PREVENTS] [SYMPTOM],"[PREVENTS]
[SYMPTOM]","herpes zoster, clinical trial",n/a,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 13:02:07,1738709176,9/15/2015 13:01:57,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[PREVENTS] [ASSOCIATED_WITH] [NONE],"[PREVENTS]
[ASSOCIATED_WITH]
[NONE]",[SIDE_EFFECT],N/A,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 13:03:00,1738709322,9/15/2015 13:02:41,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],ACYCLOVIR,none,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 13:19:45,1738713994,9/15/2015 13:19:20,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],were tested,n/a,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 13:19:50,1738714016,9/15/2015 13:18:31,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[PART_OF],[PART_OF],clinical isolates of,N/A,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 13:21:29,1738714559,9/15/2015 13:19:38,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[SIDE_EFFECT]",Susceptibilities to ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS included in clinical trial were tested by plaque reduction method.,n/a,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 13:31:48,1738717695,9/15/2015 13:31:22,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[SIDE_EFFECT],[SIDE_EFFECT],Susceptibilities ACYCLOVIR clinical isolates VARICELLA ZOSTER VIRUS,N/A,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 14:07:08,1738728550,9/15/2015 14:06:47,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],clinical trial,n/a,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 14:18:23,1738731637,9/15/2015 14:16:09,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",ACYCLOVIR clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients,n/a,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 14:31:04,1738735277,9/15/2015 14:30:44,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],isolates,N/A,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 14:41:10,1738737932,9/15/2015 14:40:49,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",A,A,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 14:46:28,1738739565,9/15/2015 14:45:45,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[OTHER],[OTHER],were tested,n/a,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 14:46:57,1738739770,9/15/2015 14:46:14,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[TREATS],[TREATS],Susceptibilities clinical trial,N/A,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660726,9/15/2015 14:56:17,1738742260,9/15/2015 14:54:07,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],were tested,N/A,121,87,137,142,96,RO-may_prevent,820390-FS1,"Susceptibilities to brovavir [1 beta D arabinofuranosyl E 5 (2 bromovinyl) uracil] and ACYCLOVIR of clinical isolates of VARICELLA ZOSTER VIRUS obtained from 58 patients with herpes zoster, included in a clinical trial of oral brovavir, were tested by a plaque reduction method.",VARICELLA ZOSTER VIRUS,ACYCLOVIR
788660727,9/15/2015 09:31:07,1738640838,9/15/2015 09:30:37,false,neodev,1,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[SYMPTOM],[SYMPTOM],increased episodes of,N/A,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 09:52:13,1738647162,9/15/2015 09:51:38,false,neodev,1,15848372,AUS,02,Jannali,14.200.59.55,[OTHER] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[OTHER]",and,n/a,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 09:54:25,1738647806,9/15/2015 09:52:50,false,clixsense,1,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],"increased episodes of consumption,",N/A,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 09:58:18,1738648759,9/15/2015 09:57:34,false,points4rewards,1,28703583,USA,"","",184.53.33.189,[PREVENTS],[PREVENTS],"also avoids the development of a clinical rebound phenomenon,",N/A,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 09:58:47,1738648875,9/15/2015 09:58:26,false,meprizescf,1,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 10:07:20,1738651240,9/15/2015 10:06:46,false,bitcoinget,1,20311164,NLD,09,Utrecht,84.105.54.251,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]","phenomenon, increased consumption,",N/A,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 10:12:19,1738652733,9/15/2015 10:10:58,false,gifthunterclub,1,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],episodes of ANGINA and NITROGLYCERIN,N/A,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 10:13:43,1738653094,9/15/2015 10:13:08,false,neodev,1,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 10:14:16,1738653314,9/15/2015 10:13:35,false,neodev,1,20961587,NLD,05,Maastricht,84.26.48.136,[CAUSES],[CAUSES],"consumption,",N/A,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 10:20:23,1738654794,9/15/2015 10:19:36,false,prodege,1,16101132,GBR,F9,Hayes,2.216.28.167,[SYMPTOM],[SYMPTOM],episodes,N/a,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 10:22:44,1738655458,9/15/2015 10:21:36,false,pocketmoneygpt,1,21432964,GBR,F8,Borehamwood,81.159.185.70,[PART_OF],[PART_OF],"episodes of ANGINA and NITROGLYCERIN consumption,",N/A,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 10:25:05,1738656120,9/15/2015 10:24:17,false,neodev,1,33644825,USA,IL,Chicago,65.60.20.67,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"This ANGINA NITROGLYCERIN consumption,",because it relases it,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 10:25:15,1738656167,9/15/2015 10:24:46,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],"ANGINA NITROGLYCERIN consumption,",N/A,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 10:27:44,1738656673,9/15/2015 10:27:33,false,elite,1,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660727,9/15/2015 10:33:17,1738658018,9/15/2015 10:32:52,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],"increased episodes of ANGINA and NITROGLYCERIN consumption,",N/A,113,124,119,118,137,RO-may_prevent,820271-FS1,"This approach also avoids the development of a clinical rebound phenomenon, as measured by increased episodes of ANGINA and NITROGLYCERIN consumption, compared with the pretreatment period, during the nitrate free interval at night and the early hours of the morning.",ANGINA,NITROGLYCERIN
788660728,9/15/2015 10:38:01,1738659187,9/15/2015 10:37:47,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treated,N/A,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 10:39:31,1738659643,9/15/2015 10:39:17,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],treated by,N/A,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 10:41:36,1738660181,9/15/2015 10:41:23,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[SYMPTOM],[SYMPTOM],month before for,n/a,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 10:43:34,1738660674,9/15/2015 10:43:22,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treated,N/A,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 10:45:07,1738661035,9/15/2015 10:44:35,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],treated,N/A,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 10:48:00,1738661765,9/15/2015 10:47:38,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],treated,Treat,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 10:52:07,1738662681,9/15/2015 10:51:55,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treated,N/A,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 10:52:47,1738662803,9/15/2015 10:52:03,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[NONE],[NONE],N/a,Not related.,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 11:02:56,1738665073,9/15/2015 11:02:44,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treated,N/A,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 11:13:56,1738668123,9/15/2015 11:13:11,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treated by,N/A,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 11:21:43,1738672124,9/15/2015 11:21:15,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],treated by HEPARIN for PULMONARY EMBOLISM,N/a,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 11:27:20,1738675251,9/15/2015 11:26:57,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treated by,N/A,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 11:30:58,1738677377,9/15/2015 11:30:10,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],treated HEPARIN 1 month before PULMONARY EMBOLISM,N/A,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 11:54:34,1738687905,9/15/2015 11:54:12,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],treated,n/a,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660728,9/15/2015 12:11:58,1738693435,9/15/2015 12:10:55,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treated,N/A,59,32,77,76,39,RO-may_prevent,820392-FS1,One patient had been treated by HEPARIN 1 month before for PULMONARY EMBOLISM and the other had had a coronary angiography and bypass graft surgery 5 months before for silent myocardial infarction.,PULMONARY EMBOLISM,HEPARIN
788660729,9/15/2015 10:39:04,1738659470,9/15/2015 10:38:45,false,elite,1.0,30659677,USA,"","",162.252.172.126,[PREVENTS],[PREVENTS],Prevention,N/A,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 10:41:24,1738660171,9/15/2015 10:41:03,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],Uses Acidosis Prevention,N/A,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 10:42:45,1738660465,9/15/2015 10:42:31,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 10:44:30,1738660864,9/15/2015 10:44:18,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[PREVENTS],[PREVENTS],Prevention,N/A,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 10:50:02,1738662199,9/15/2015 10:48:56,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[PREVENTS],[PREVENTS],Prevention correction,N/A,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 10:51:59,1738662673,9/15/2015 10:51:20,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,Associated,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 10:53:08,1738662928,9/15/2015 10:52:50,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],Prevention,N/A,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 10:55:44,1738663541,9/15/2015 10:55:24,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[PREVENTS],[PREVENTS],Prevention,N/a,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 11:04:06,1738665336,9/15/2015 11:03:53,false,elite,1.0,30659615,USA,"","",162.250.145.234,[PREVENTS],[PREVENTS],Prevention,N/A,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 11:28:13,1738675957,9/15/2015 11:26:41,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER] [PART_OF],"[PART_OF]
[OTHER]",Uses,N/A,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 11:33:14,1738678308,9/15/2015 11:32:46,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[PREVENTS],[PREVENTS],Prevention of,N/A,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 11:35:52,1738679417,9/15/2015 11:34:18,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],THAM Uses Acidosis Prevention ACIDOSIS,N/A,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 11:56:55,1738688685,9/15/2015 11:56:25,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],correction,n/a,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 12:15:02,1738694598,9/15/2015 12:14:33,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660729,9/15/2015 12:15:15,1738694656,9/15/2015 12:14:12,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[PREVENTS],[PREVENTS],ACIDOSIS,NONE,176,115,135,183,119,RO-may_treat,820030-FS1,"a ,   100  Class:  Alkalinizing Agents 40:08; TN900 (VA)  Synonyms:  Tris Buffer; Tris(hydroxymethyl)aminomethane; THAM  Uses  Acidosis  Prevention and correction of metabolic ACIDOSIS associated with cardiac bypass surgery.",ACIDOSIS,THAM
788660730,9/15/2015 09:39:01,1738643543,9/15/2015 09:38:27,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],interactions of,N/A,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 09:56:15,1738648269,9/15/2015 09:55:57,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[PART_OF],[PART_OF],and,n/a,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:02:12,1738649749,9/15/2015 10:01:51,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,n/a,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:05:18,1738650673,9/15/2015 10:03:41,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],interactions,N/A,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:06:19,1738650932,9/15/2015 10:05:12,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis and management are reviewed.,N/A,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:10:57,1738652340,9/15/2015 10:10:30,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",are reviewed.,N/A,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:17:40,1738654167,9/15/2015 10:17:18,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],including,N/A,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:19:28,1738654563,9/15/2015 10:19:00,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[IS_A],[IS_A],and,N/A,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:22:40,1738655435,9/15/2015 10:21:53,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],The diagnosis,N/A,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:24:37,1738655993,9/15/2015 10:24:10,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[ASSOCIATED_WITH],[ASSOCIATED_WITH],interactions,N/a,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:29:38,1738657126,9/15/2015 10:29:24,false,elite,1.0,30659754,USA,"","",162.250.145.204,[MANIFESTATION],[MANIFESTATION],interactions,N/A,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:30:32,1738657365,9/15/2015 10:29:37,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],management of malaria,N/A,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:31:34,1738657562,9/15/2015 10:31:02,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",ANTIMALARIAL DRUGS MALARIA WITH HIV,yes,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:34:29,1738658306,9/15/2015 10:34:16,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CONTRAINDICATES],[CONTRAINDICATES],interactions,N/A,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660730,9/15/2015 10:36:16,1738658697,9/15/2015 10:34:53,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[OTHER],[OTHER],safety interactions,N/A,117,78,124,135,96,RO-may_prevent,820152-FS1,"The diagnosis and management of malaria in pregnancy, including the safety of ANTIMALARIAL DRUGS and interactions of MALARIA WITH HIV IN pregnancy are reviewed.",MALARIA WITH HIV IN,ANTIMALARIAL DRUGS
788660731,9/15/2015 12:35:15,1738701737,9/15/2015 12:34:13,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],"dactinomycin,",NONE,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 12:52:34,1738706658,9/15/2015 12:52:19,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[NONE],[NONE],very good,very good,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 12:58:21,1738708097,9/15/2015 12:57:50,false,elite,1.0,28548715,USA,"","",38.95.108.245,[TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]",Commonly used,n/a,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 13:00:24,1738708602,9/15/2015 12:59:57,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[PREVENTS] [LOCATION] [ASSOCIATED_WITH] [NONE],"[PREVENTS]
[LOCATION]
[ASSOCIATED_WITH]
[NONE]",[TREATS],N/A,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 13:00:51,1738708770,9/15/2015 13:00:34,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],CYCLOPHOSPHAMIDE,none,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 13:07:53,1738710647,9/15/2015 13:05:39,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"RHABDOMYOSARCOMA Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE",n/a,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 13:08:36,1738710817,9/15/2015 13:07:24,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[OTHER],[OTHER],Commonly used with,N/A,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 13:16:45,1738713031,9/15/2015 13:16:25,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],Commonly used,n/a,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 13:28:23,1738716904,9/15/2015 13:27:57,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RHABDOMYOSARCOMA Commonly used with CYCLOPHOSPHAMIDE,N/A,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 13:39:26,1738721933,9/15/2015 13:39:10,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[OTHER],[OTHER],with or without,n/a,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 14:04:27,1738727843,9/15/2015 14:04:05,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],used,n/a,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 14:11:26,1738729611,9/15/2015 14:10:58,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE",n/a,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 14:28:07,1738734504,9/15/2015 14:27:37,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[OTHER],[OTHER],used with,n/A,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 14:38:57,1738737251,9/15/2015 14:38:32,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[CAUSES] [OTHER] [NONE],"[CAUSES]
[OTHER]
[NONE]",N,very nice,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660731,9/15/2015 14:39:47,1738737488,9/15/2015 14:38:45,false,onestopgpt,1,21275875,CAN,ON,Hamilton,24.36.124.79,[TREATS],[TREATS],used with adjunct to surgery,N/A,5,72,21,20,88,RO-may_treat,820032-FS1,"136  RHABDOMYOSARCOMA  Commonly used with dactinomycin, with or without CYCLOPHOSPHAMIDE as an adjunct to surgery and/or radiation therapy.",RHABDOMYOSARCOMA,CYCLOPHOSPHAMIDE
788660732,9/15/2015 09:28:32,1738640129,9/15/2015 09:27:48,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[SYMPTOM],[SYMPTOM],virus,N/A,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 09:46:31,1738645694,9/15/2015 09:44:35,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[NONE],[NONE],N/A,A long list of terms,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 09:49:27,1738646303,9/15/2015 09:48:35,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HBV hepatitis B virus HBSAG hepatitis,n/a,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 09:53:39,1738647632,9/15/2015 09:52:48,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],orally prn as needed,N/A,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 09:56:30,1738648307,9/15/2015 09:55:58,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 10:04:35,1738650480,9/15/2015 10:03:38,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",tests,N/A,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 10:05:36,1738650753,9/15/2015 10:04:29,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[PART_OF],[PART_OF],HBV hepatitis B virus HBSAG hepatitis B surface antigen,N/A,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 10:09:31,1738651816,9/15/2015 10:08:48,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[IS_A],[IS_A],virus,N/A,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 10:11:00,1738652384,9/15/2015 10:09:34,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[PART_OF],[PART_OF],hepatitis,N/A,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 10:15:17,1738653537,9/15/2015 10:13:23,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[PART_OF],[PART_OF],tests,N/a,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 10:16:40,1738653956,9/15/2015 10:15:48,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],virus,N/A,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 10:19:35,1738654596,9/15/2015 10:18:53,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[CAUSES],[CAUSES],HCV hepatitis virus herpes international LFTs function LMWH B PUVA,treat,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 10:22:01,1738655218,9/15/2015 10:21:07,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HBV hepatitis B virus HBSAG,n/a,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 10:26:22,1738656413,9/15/2015 10:26:11,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CAUSES],[CAUSES],surface,N/A,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660732,9/15/2015 10:32:09,1738657712,9/15/2015 10:31:52,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],hepatitis,N/A,0,26,3,2,31,RO-may_prevent,820310-FS1,HBV    hepatitis B virus  HBSAG    hepatitis B surface antigen  HCV    hepatitis C virus  HSV    herpes simplex virus  im    intramuscular  IU    international units  IgG    immunoglobulin G  IgM    immunoglobulin M  LFTs    liver function tests  LMWH    low molecular weight heparin  NBUVB    narrowband ultraviolet B  NSAID    nonsteroidal anti inflammatory drug  OR    odds ratio  po    orally  prn    as needed  PUVA    psoralen and ultraviolet A  RNA    ribonucleic acid  sc    subcutaneous.,HBV,HBSAG
788660733,9/15/2015 10:47:57,1738661744,9/15/2015 10:47:42,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],increases,N/A,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 10:57:28,1738663870,9/15/2015 10:56:45,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[OTHER],[OTHER],no evidence,N/A,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 11:01:42,1738664803,9/15/2015 11:01:09,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[CAUSES],[CAUSES],increases risk,Cause,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 11:03:22,1738665158,9/15/2015 11:02:52,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[PREVENTS],[PREVENTS],isotretinoin users with acne,N/a,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 11:08:07,1738666285,9/15/2015 11:07:53,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],based,N/A,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 11:41:38,1738681970,9/15/2015 11:40:56,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[CAUSES],[CAUSES],users with,N/A,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 11:47:00,1738684521,9/15/2015 11:46:16,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[CAUSES],[CAUSES],ACNE showed no evidence that ISOTRETINOIN,N/A,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 11:47:17,1738684635,9/15/2015 11:45:14,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",users with,N/A,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 12:06:16,1738691408,9/15/2015 12:05:55,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],study,n/a,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 12:26:24,1738698521,9/15/2015 12:25:33,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[CAUSES],[CAUSES],evidence,N/A,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 12:27:31,1738698885,9/15/2015 12:27:00,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[SYMPTOM],[SYMPTOM],"depression,",NONE,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 12:50:33,1738706201,9/15/2015 12:50:14,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",very good,very good,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 12:53:38,1738706914,9/15/2015 12:52:41,false,elite,1.0,28548715,USA,"","",38.95.108.245,[PREVENTS] [CAUSES],"[PREVENTS]
[CAUSES]",evidence,n/a,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 12:54:20,1738707055,9/15/2015 12:53:23,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[CONTRAINDICATES],[CONTRAINDICATES],showed no evidence,N/A,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660733,9/15/2015 12:54:31,1738707084,9/15/2015 12:52:50,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],oral antibiotic users ACNE ISOTRETINOIN,n/a,116,145,77,119,157,RO-may_treat,820037-FS1,"• A large, population based cohort study of 7195 isotretinoin users with acne and 13,700 oral antibiotic users with ACNE showed no evidence that ISOTRETINOIN increases risk of depression, suicide, or other psychiatric disorders ( 34.",ACNE,ISOTRETINOIN
788660734,9/15/2015 12:30:00,1738699739,9/15/2015 12:29:43,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 12:34:12,1738701245,9/15/2015 12:33:25,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],TUBERCULOSIS,NONE,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 12:52:19,1738706615,9/15/2015 12:52:04,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[NONE],[NONE],very good,very good,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 12:57:48,1738707970,9/15/2015 12:57:18,false,elite,1.0,28548715,USA,"","",38.95.108.245,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",drug treatment,n/a,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 12:59:54,1738708491,9/15/2015 12:59:43,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[PREVENTS] [TREATS] [SIDE_EFFECT] [NONE],"[TREATS]
[PREVENTS]
[SIDE_EFFECT]
[NONE]",[TREATS],N/A,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 13:00:34,1738708679,9/15/2015 13:00:15,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ISONIAZID,none,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 13:05:38,1738710025,9/15/2015 13:04:22,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],treatment of TUBERCULOSIS ISONIAZID,n/a,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 13:07:24,1738710500,9/15/2015 13:06:25,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[TREATS],[TREATS],in the presence of,N/A,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 13:16:24,1738712914,9/15/2015 13:16:00,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[CONTRAINDICATES],[CONTRAINDICATES],restricted,n/a,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 13:27:56,1738716786,9/15/2015 13:27:23,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[SIDE_EFFECT],[SIDE_EFFECT],TUBERCULOSIS degradation of Rifampicin in presence of ISONIAZID,N/A,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 13:39:10,1738721871,9/15/2015 13:38:56,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[TREATS],[TREATS],treatment,n/a,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 13:55:24,1738725680,9/15/2015 13:54:54,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],treatment of TUBERCULOSIS restricted degradation of Rifampicin presence ISONIAZID,n/a,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 14:04:04,1738727738,9/15/2015 14:03:46,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],treatment,n/a,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 14:27:36,1738734370,9/15/2015 14:26:49,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[NONE],[NONE],n/A,"Isoniazid is related to Rifampicin, but not Tuberculosis.",54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660734,9/15/2015 14:38:31,1738737132,9/15/2015 14:38:06,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",N,Good,54,141,66,65,150,RO-may_prevent,820312-FS1,The use of multiple drug regimes for the treatment of TUBERCULOSIS is restricted because of the degradation of Rifampicin in the presence of ISONIAZID,TUBERCULOSIS,ISONIAZID
788660735,9/15/2015 10:36:07,1738658638,9/15/2015 10:35:53,false,elite,1.0,30659677,USA,"","",162.252.172.126,[PREVENTS],[PREVENTS],resistant,N/A,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 10:36:56,1738658881,9/15/2015 10:36:27,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[CAUSES],[CAUSES],Severe exacerbation of acne during oral,N/A,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 10:38:52,1738659434,9/15/2015 10:38:40,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[MANIFESTATION],[MANIFESTATION],SEVERE NODULAR ACNE ISOTRETINOIN,n/a,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 10:40:07,1738659828,9/15/2015 10:38:51,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[OTHER],[OTHER],resistant,N/A,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 10:40:29,1738659937,9/15/2015 10:39:00,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],therapy,Treat,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 10:41:37,1738660183,9/15/2015 10:41:26,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[PREVENTS],[PREVENTS],resistant,N/A,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 10:48:41,1738661910,9/15/2015 10:48:09,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[NONE],[NONE],N/a,Two unrelated terms.,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 10:50:05,1738662230,9/15/2015 10:49:54,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],"potential,",N/A,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 11:00:00,1738664397,9/15/2015 10:59:43,false,elite,1.0,30659615,USA,"","",162.250.145.234,[OTHER],[OTHER],Positive,N/A,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 11:01:25,1738664745,9/15/2015 11:00:13,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],Clinical Alerts:,N/A,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 11:16:36,1738669397,9/15/2015 11:15:43,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],SEVERE NODULAR ACNE ISOTRETINOIN therapy,N/a,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 11:20:30,1738671284,9/15/2015 11:19:08,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Severe exacerbation during therapy,N/A,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 11:24:33,1738673774,9/15/2015 11:23:31,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],Severe exacerbation of acne during oral ISOTRETINOIN,N/A,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 11:33:56,1738678672,9/15/2015 11:33:33,false,elite,1,33798502,USA,VA,Manassas,207.244.86.193,[PREVENTS],[PREVENTS],ISOTRETINOIN,N/A,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660735,9/15/2015 11:49:23,1738685566,9/15/2015 11:48:34,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[CAUSES],[CAUSES],exacerbation,n/a,193,370,212,211,382,RO-may_treat,820038-FS1,"ALERT TRIGGERS  Clinical Alerts: • Positive serum and urine human chorionic gonadotropin (HCG) • Female of childbearing potential, sexually active, on oral isotretinoin or topical tazarotene • SEVERE NODULAR ACNE resistant to oral antibiotics • Mood swings or depression • Doxycycline use in outdoor worker, sunbather, or skier • Severe exacerbation of acne during oral ISOTRETINOIN therapy • Elevated triglycerides or cholesterol  Data Elements: • Acne history: duration, chronicity, severity, family history, current and prior medications • Acne physical exam: distribution, noninflammatory lesions (estimate.",SEVERE NODULAR ACNE,ISOTRETINOIN
788660736,9/15/2015 09:32:21,1738641151,9/15/2015 09:32:01,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],treated in,N/A,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 09:54:19,1738647793,9/15/2015 09:53:04,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[TREATS],[TREATS],were treated with,n/a,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 09:58:40,1738648846,9/15/2015 09:57:08,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treated,N/A,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 10:00:21,1738649235,9/15/2015 10:00:04,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treated,n/a,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 10:01:07,1738649447,9/15/2015 10:00:40,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],were treated,N/A,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 10:08:50,1738651667,9/15/2015 10:08:28,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS],[TREATS],treated,N/A,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 10:15:33,1738653614,9/15/2015 10:15:11,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treated,N/A,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 10:15:35,1738653619,9/15/2015 10:15:19,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],treated,N/A,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 10:15:39,1738653639,9/15/2015 10:14:41,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treated,N/A,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 10:21:07,1738654979,9/15/2015 10:20:46,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],treated,N/a,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 10:26:02,1738656361,9/15/2015 10:24:48,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],were treated in,N/A,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 10:27:13,1738656554,9/15/2015 10:26:44,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[CAUSES],[CAUSES],Blocks bovine FLUORIDE DENTIFRICE,treats,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 10:28:24,1738656830,9/15/2015 10:28:13,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],treated,N/A,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 10:33:39,1738658090,9/15/2015 10:33:18,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],were treated in vitro with FLUORIDE DENTIFRICE,N/A,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660736,9/15/2015 10:33:52,1738658132,9/15/2015 10:33:22,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],treated,N/A,72,141,78,77,160,RO-may_prevent,820159-FS1,"Blocks of bovine enamel, covered with a steel mesh or a steel mesh plus PLAQUE or with neither, were treated in vitro with a 20% slurry of a FLUORIDE DENTIFRICE for 1 h.",PLAQUE,FLUORIDE DENTIFRICE
788660737,9/15/2015 10:47:13,1738661561,9/15/2015 10:47:01,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[SIDE_EFFECT],[SIDE_EFFECT],efficacy,N/A,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 10:56:07,1738663636,9/15/2015 10:55:50,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],against,N/A,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 10:59:50,1738664366,9/15/2015 10:59:06,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[SIDE_EFFECT],[SIDE_EFFECT],increased capillary,Side effect,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 11:01:51,1738664827,9/15/2015 11:01:36,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],Decreases,N/a,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 11:07:22,1738666075,9/15/2015 11:06:57,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 11:40:01,1738681129,9/15/2015 11:39:42,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],Decreases,N/A,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 11:42:56,1738682450,9/15/2015 11:42:21,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],Decreases,N/A,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 11:44:24,1738683154,9/15/2015 11:43:32,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],(PREDNISONE Decreases INFLAMMATION,N/A,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 12:05:17,1738691140,9/15/2015 12:03:00,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],Decreases,n/a,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 12:24:41,1738698051,9/15/2015 12:23:45,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[PREVENTS],[PREVENTS],Decreases,N/A,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 12:26:01,1738698423,9/15/2015 12:24:52,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[MANIFESTATION],[MANIFESTATION],INFLAMMATION,NONE,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 12:45:32,1738704901,9/15/2015 12:44:40,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",none,very good,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 12:50:44,1738706234,9/15/2015 12:50:04,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[TREATS] [CONTRAINDICATES],"[TREATS]
[CONTRAINDICATES]",There are no controlled trials that show a clinical utility Decreases,"Contraindicates for the condition.
BUT it does reduce inflammation juts not is a useful way to treat to disease causing the inflamation",523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 12:50:49,1738706248,9/15/2015 12:48:09,false,elite,1.0,28548715,USA,"","",38.95.108.245,[NONE],[NONE],n/a,I do not see any relation,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660737,9/15/2015 12:52:03,1738706566,9/15/2015 12:51:01,false,neodev,1.0,34081836,USA,CA,San Jose,173.245.65.34,[TREATS],[TREATS],(PREDNISONE Decreases INFLAMMATION,PREDNISONE Decreases INFLAMMATION,523,501,536,534,511,RO-may_treat,820039-FS1,Anecdotal reports of efficacy of penicillin G with or without silymarin/silibinin in ALF due to Amanita phalloides Antifungal agent (fluconazole)  Prophylaxis against fungal sepsis  100 200 mg po or iv; continue for the interval of compromised liver function  Prophylactic use of no proven benefit in patients with ALF  May interfere with other medications through CYP P450  There are no controlled trials of prophylactic antifungals that show a clinical utility in patients with ALF Corticosteroids (PREDNISONE  Decreases INFLAMMATION by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability  20 mg/d.,INFLAMMATION,PREDNISONE
788660738,9/15/2015 12:37:20,1738702432,9/15/2015 12:36:19,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],venous thrombosis,NONE,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 12:53:20,1738706864,9/15/2015 12:53:07,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[NONE],[NONE],very good,very good,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 12:59:31,1738708410,9/15/2015 12:59:07,false,elite,1.0,28548715,USA,"","",38.95.108.245,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",therapy,n/a,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 13:01:14,1738708876,9/15/2015 13:01:00,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[TREATS] [CAUSES] [CONTRAINDICATES] [ASSOCIATED_WITH] [NONE],"[TREATS]
[CAUSES]
[CONTRAINDICATES]
[ASSOCIATED_WITH]
[NONE]",[SIDE_EFFECT],N/A,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 13:01:36,1738708934,9/15/2015 13:01:22,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],HEPARIN,none,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 13:11:05,1738711482,9/15/2015 13:10:10,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],HEPARIN mainstays of therapy of PULMONARY EMBOLISM,n/a,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 13:11:36,1738711632,9/15/2015 13:10:40,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[TREATS],[TREATS],mainstays of the therapy,N/A,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 13:18:09,1738713542,9/15/2015 13:17:53,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],mainstays of therapy,n/a,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 13:29:39,1738717253,9/15/2015 13:29:15,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],HEPARIN mainstays of the therapy PULMONARY EMBOLISM,N/A,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 14:05:21,1738728077,9/15/2015 14:05:04,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],therapy,n/a,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 14:14:05,1738730280,9/15/2015 14:12:16,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],HEPARIN mainstays the therapy deep venous thrombosis and PULMONARY EMBOLISM,n/a,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 14:29:43,1738734938,9/15/2015 14:29:23,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],therapy,N/A,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 14:39:44,1738737485,9/15/2015 14:39:29,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[TREATS] [NONE],"[TREATS]
[NONE]",A,A,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 14:43:15,1738738613,9/15/2015 14:42:30,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[TREATS],[TREATS],therapy,N/A,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660738,9/15/2015 14:43:16,1738738624,9/15/2015 14:42:43,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],mainstays of the therapy,n/a,115,19,133,132,26,RO-may_prevent,820316-FS1,Intravenous use of HEPARIN and oral anticoagulation are the mainstays of the therapy of deep venous thrombosis and PULMONARY EMBOLISM,PULMONARY EMBOLISM,HEPARIN
788660739,9/15/2015 13:02:52,1738709303,9/15/2015 13:02:40,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[TREATS] [LOCATION] [CONTRAINDICATES] [NONE],"[TREATS]
[LOCATION]
[CONTRAINDICATES]
[NONE]",[SIDE_EFFECT],N/A,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 13:02:57,1738709319,9/15/2015 13:02:42,false,elite,1.0,28548715,USA,"","",38.95.108.245,[CAUSES],[CAUSES],caused,n/a,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 13:03:59,1738709568,9/15/2015 13:03:43,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[CAUSES],[CAUSES],ARRHYTHMIAS,none,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 13:20:50,1738714299,9/15/2015 13:20:28,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[OTHER],[OTHER],resistant to most common ANTIARRHYTHMIC AGENTS,n/a,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 13:27:01,1738716575,9/15/2015 13:24:58,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[IS_A] [PART_OF] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",ARRHYTHMIAS common ANTIARRHYTHMIC AGENTS,n/a,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 13:33:04,1738718038,9/15/2015 13:32:40,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[CAUSES],[CAUSES],ARRHYTHMIAS caused by most common ANTIARRHYTHMIC AGENTS,N/A,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 14:08:12,1738728839,9/15/2015 14:07:49,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[OTHER],[OTHER],resistant,n/a,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 14:27:36,1738734371,9/15/2015 14:27:06,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[CAUSES],[CAUSES],ARRHYTHMIAS caused by varicella myocarditis were most common ANTIARRHYTHMIC AGENTS,n/a,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 14:32:17,1738735572,9/15/2015 14:31:47,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[CAUSES],[CAUSES],caused by,N/A,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 14:42:28,1738738421,9/15/2015 14:41:53,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",N/A,N/A,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 14:49:56,1738740590,9/15/2015 14:49:06,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[ASSOCIATED_WITH],[ASSOCIATED_WITH],resistant,N/A,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 15:01:35,1738743895,9/15/2015 15:01:02,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[OTHER],[OTHER],resistant to most common,N/A,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 15:08:15,1738746698,9/15/2015 15:06:32,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],resistant,N/A,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 15:17:10,1738750823,9/15/2015 15:16:35,false,neodev,1.0,34431172,CAN,AB,Edmonton,208.123.223.129,[PREVENTS] [TREATS] [NONE],"[TREATS]
[PREVENTS]
[NONE]",no,no,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660739,9/15/2015 15:57:46,1738764353,9/15/2015 15:55:00,false,instagc,1,33058612,USA,IL,Glenview,162.229.106.229,[OTHER],[OTHER],resistant to,N/A,6,103,17,16,124,RO-may_prevent,820280-FS1,These ARRHYTHMIAS were thought to be caused by varicella myocarditis and were resistant to most common ANTIARRHYTHMIC AGENTS,ARRHYTHMIAS,ANTIARRHYTHMIC AGENTS
788660740,9/15/2015 13:03:08,1738709357,9/15/2015 13:02:55,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[SYMPTOM] [CONTRAINDICATES] [NONE],"[SYMPTOM]
[CONTRAINDICATES]
[NONE]",[PREVENTS],N/A,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 13:03:19,1738709385,9/15/2015 13:02:59,false,elite,1.0,28548715,USA,"","",38.95.108.245,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",TREATMENT GROUP,n/a,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 13:04:17,1738709687,9/15/2015 13:03:59,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],NIDDM,none,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 13:21:09,1738714431,9/15/2015 13:20:51,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],randomly assigned,n/a,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 13:28:53,1738717047,9/15/2015 13:27:02,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"In prospective study, patients with NIDDM randomly assigned to INJECTION TREATMENT GROUP",n/a,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 13:33:27,1738718135,9/15/2015 13:33:06,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],NIDDM randomly multiple INSULIN INJECTION TREATMENT GROUP (MIT group),N/A,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 14:08:32,1738728895,9/15/2015 14:08:14,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],TREATMENT,n/a,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 14:28:13,1738734542,9/15/2015 14:27:37,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]","prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP treatment",n/a,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 14:32:34,1738735640,9/15/2015 14:32:18,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],injection treatment,N/A,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 14:42:44,1738738482,9/15/2015 14:42:30,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[PREVENTS] [CAUSES] [NONE],"[PREVENTS]
[CAUSES]
[NONE]",N/A,N/A,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 14:50:44,1738740869,9/15/2015 14:49:57,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[TREATS],[TREATS],randomly assigned,N/A,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 15:02:14,1738744171,9/15/2015 15:01:37,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[TREATS],[TREATS],treatment group,N/A,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 15:09:35,1738747303,9/15/2015 15:08:17,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],TREATMENT,N/A,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 15:17:48,1738751151,9/15/2015 15:17:11,false,neodev,1.0,34431172,CAN,AB,Edmonton,208.123.223.129,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",no,no,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660740,9/15/2015 16:00:42,1738765942,9/15/2015 15:59:14,false,clixsense,1,32053717,GBR,"","",51.174.76.80,[TREATS] [PREVENTS] [ASSOCIATED_WITH] [CAUSES],"[TREATS]
[PREVENTS]
[CAUSES]
[ASSOCIATED_WITH]",NIDDM INSULIN INJECTION TREATMENT insulin injection,there is relation,53,96,58,57,129,RO-may_treat,820043-FS1,"• In a prospective study, 110 Japanese patients with NIDDM were randomly assigned to a multiple INSULIN INJECTION TREATMENT GROUP (MIT group) or to a conventional insulin injection treatment group (CIT group.",NIDDM,INSULIN INJECTION TREATMENT GROUP
788660741,9/15/2015 09:29:22,1738640360,9/15/2015 09:28:58,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],decrease,N/A,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 09:48:13,1738646035,9/15/2015 09:47:06,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",therapeutic regimens,N/A,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 09:50:24,1738646654,9/15/2015 09:50:03,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[SYMPTOM],[SYMPTOM],expedite,n/a,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 09:54:59,1738647968,9/15/2015 09:54:29,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],higher dosages may expedite,N/A,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 09:57:10,1738648486,9/15/2015 09:56:54,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[CAUSES],[CAUSES],expedite,n/a,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 10:05:08,1738650617,9/15/2015 10:04:51,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",may expedite,N/A,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 10:07:13,1738651213,9/15/2015 10:06:18,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],higher dosages may expedite,N/A,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 10:10:31,1738652194,9/15/2015 10:10:05,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],expedite,N/A,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 10:11:58,1738652619,9/15/2015 10:11:33,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],healing.,N/A,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 10:18:20,1738654325,9/15/2015 10:17:45,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[ASSOCIATED_WITH],[ASSOCIATED_WITH],healing.,N/a,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 10:18:25,1738654337,9/15/2015 10:17:36,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],higher dosages may expedite healing.,N/A,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 10:20:36,1738654853,9/15/2015 10:19:59,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],"RANITIDINE submaximally, expedite DUODENAL ULCER",prevent,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 10:22:57,1738655489,9/15/2015 10:22:27,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],higher dosages may expedite DUODENAL ULCER healing.,n/a,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 10:26:50,1738656494,9/15/2015 10:26:39,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SYMPTOM],[SYMPTOM],intragastric,N/A,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660741,9/15/2015 10:32:21,1738657750,9/15/2015 10:32:10,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],dosages,N/A,123,35,137,136,45,RO-may_prevent,820165-FS1,"As current therapeutic regimens of RANITIDINE decrease 24 h intragastric acidity submaximally, higher dosages may expedite DUODENAL ULCER healing.",DUODENAL ULCER,RANITIDINE
788660742,9/15/2015 12:53:48,1738706944,9/15/2015 12:53:36,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[NONE],[NONE],very good,very good,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 13:00:37,1738708722,9/15/2015 13:00:05,false,elite,1.0,28548715,USA,"","",38.95.108.245,[CAUSES] [TREATS] [SYMPTOM],"[TREATS]
[CAUSES]
[SYMPTOM]",coronary artery disease,n/a,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 13:01:42,1738708978,9/15/2015 13:01:31,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS] [MANIFESTATION] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[NONE]",[SIDE_EFFECT],N/A,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 13:02:20,1738709202,9/15/2015 13:01:58,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],CORONARY ARTERY DISEASE,none,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 13:14:38,1738712419,9/15/2015 13:13:07,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",100 patients with coronary artery disease were randomized to atorvastatin and placebo.,n/a,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 13:16:41,1738713029,9/15/2015 13:14:22,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[OTHER] [TREATS],"[TREATS]
[OTHER]",were randomized to,N/A,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 13:18:54,1738713736,9/15/2015 13:18:36,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],randomized to atorvastatin,n/a,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 13:30:47,1738717465,9/15/2015 13:30:18,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],CORONARY ARTERY DISEASE randomized ATORVASTATIN 40 mg/day,N/A,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 14:06:27,1738728380,9/15/2015 14:06:05,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],randomized,n/a,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 14:15:29,1738730734,9/15/2015 14:14:38,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],CORONARY ARTERY DISEASE were randomized to atorvastatin 40 mg/day,n/a,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 14:30:29,1738735153,9/15/2015 14:30:09,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],were randomized to,N/A,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 14:40:28,1738737634,9/15/2015 14:40:03,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",A,A,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 14:44:39,1738738997,9/15/2015 14:43:56,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS] [OTHER],"[TREATS]
[OTHER]",randomized to,n/a,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 14:45:17,1738739207,9/15/2015 14:44:46,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[TREATS],[TREATS],randomized,N/A,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660742,9/15/2015 14:48:31,1738740246,9/15/2015 14:47:51,false,clixsense,1.0,24204845,GBR,L3,Rotherham,86.162.168.250,[TREATS],[TREATS],CORONARY ARTERY DISEASE randomized to ATORVASTATIN,N/A,56,163,52,78,175,RO-may_prevent,820166-FS1,A total of 100 patients with coronary artery disease or CORONARY ARTERY DISEASE equivalent were randomized to atorvastatin 40 mg/day and ezetimibe 10 mg/day or to ATORVASTATIN 40 mg/day and placebo.,CORONARY ARTERY DISEASE,ATORVASTATIN
788660743,9/15/2015 09:38:26,1738643283,9/15/2015 09:38:04,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[SYMPTOM],[SYMPTOM],studied were,N/A,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 09:55:56,1738648224,9/15/2015 09:55:39,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[PART_OF],[PART_OF],markers studied were,n/a,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:01:49,1738649667,9/15/2015 10:01:35,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:03:40,1738650230,9/15/2015 10:02:33,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[IS_A],[IS_A],markers,N/A,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:05:08,1738650616,9/15/2015 10:04:07,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[MANIFESTATION],[MANIFESTATION],"markers studied and if positive,",N/A,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:10:28,1738652166,9/15/2015 10:10:05,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",markers studied and if,N/A,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:17:17,1738654062,9/15/2015 10:16:38,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[OTHER],[OTHER],studied,N/A,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:18:59,1738654454,9/15/2015 10:17:57,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",markers,N/A,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:21:51,1738655159,9/15/2015 10:20:37,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[PART_OF],[PART_OF],HEPATITIS B markers studied were HBs ANTIGEN (HBSAG),N/A,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:24:09,1738655844,9/15/2015 10:22:27,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[ASSOCIATED_WITH],[ASSOCIATED_WITH],studied,N/a,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:29:23,1738657085,9/15/2015 10:29:11,false,elite,1.0,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:29:36,1738657111,9/15/2015 10:28:29,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],markers studied,N/A,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:31:00,1738657464,9/15/2015 10:29:54,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[PREVENTS],[PREVENTS],HEPATITIS B HBs ANTIGEN (HBSAG) HBV DNA.,prevents,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:34:15,1738658255,9/15/2015 10:34:03,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],studied,N/A,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660743,9/15/2015 10:34:58,1738658430,9/15/2015 10:34:35,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",HEPATITIS B markers studied were HBs ANTIGEN (HBSAG),N/A,0,37,11,10,52,RO-may_prevent,820288-FS1,"HEPATITIS B markers studied were HBs ANTIGEN (HBSAG) and if positive, HBe antigen/anti HBe antibodies and HBV DNA.",HEPATITIS B,ANTIGEN (HBSAG)
788660744,9/15/2015 12:29:41,1738699618,9/15/2015 12:28:48,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[MANIFESTATION],[MANIFESTATION],responsible,N/A,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 12:33:25,1738700943,9/15/2015 12:32:32,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[LOCATION],[LOCATION],PLAQUE between,NONE,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 12:52:02,1738706565,9/15/2015 12:51:47,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",very good,very good,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 12:57:17,1738707865,9/15/2015 12:56:55,false,elite,1.0,28548715,USA,"","",38.95.108.245,[CAUSES],[CAUSES],responsible,n/a,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 12:59:40,1738708440,9/15/2015 12:59:29,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[CAUSES] [ASSOCIATED_WITH] [NONE],"[CAUSES]
[ASSOCIATED_WITH]
[NONE]",[TREATS],N/A,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 13:00:15,1738708547,9/15/2015 13:00:01,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],FLUORIDE,none,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 13:04:21,1738709691,9/15/2015 13:02:35,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[CAUSES],[CAUSES],high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for FLUORIDE concentration in,n/a,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 13:06:24,1738710236,9/15/2015 13:04:06,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[CONTRAINDICATES],[CONTRAINDICATES],poor correlation,N/A,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 13:15:59,1738712792,9/15/2015 13:15:29,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],high fluoride LEVELS responsible for relatively low caries,n/a,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 13:27:22,1738716647,9/15/2015 13:26:20,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[PREVENTS],[PREVENTS],fluoride LEVELS IN THE PLAQUE RESERVOIR correlation FLUORIDE concentration in drinking water.,N/A,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 13:38:55,1738721787,9/15/2015 13:38:44,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[CAUSES],[CAUSES],responsible,n/a,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 13:54:54,1738725556,9/15/2015 13:54:08,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[CAUSES],[CAUSES],LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low poor correlation between dental caries experience and concentration drinking water.,n/a,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 14:03:45,1738727675,9/15/2015 14:03:06,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[CAUSES],[CAUSES],responsible,n/a,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 14:26:49,1738734198,9/15/2015 14:25:55,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[ASSOCIATED_WITH],[ASSOCIATED_WITH],IN,n/A,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660744,9/15/2015 14:38:45,1738737178,9/15/2015 14:35:51,false,onestopgpt,1.0,21275875,CAN,ON,Hamilton,24.36.124.79,[LOCATION],[LOCATION],PLAQUE RESERVOIR,N/A,40,258,60,72,266,RO-may_prevent,820201-FS1,"It is postulated that the high fluoride LEVELS IN THE PLAQUE RESERVOIR IS responsible for the relatively low caries experience, the significant differences in caries experience between the groups and the poor correlation between dental caries experience and FLUORIDE concentration in drinking water.",LEVELS IN THE PLAQUE RESERVOIR IS,FLUORIDE
788660745,9/15/2015 09:22:39,1738638805,9/15/2015 09:22:18,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],treated with,N/A,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 09:25:23,1738639467,9/15/2015 09:24:14,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[OTHER],[OTHER],are treated with,N/A,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 09:29:51,1738640502,9/15/2015 09:27:36,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treated,N/A,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 09:41:21,1738644211,9/15/2015 09:40:37,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[MANIFESTATION],[MANIFESTATION],Salutary effects,N/A,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 09:43:25,1738644884,9/15/2015 09:43:08,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[OTHER],[OTHER],treated with,n/a,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 09:51:10,1738646896,9/15/2015 09:50:54,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treated,n/a,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 09:54:02,1738647735,9/15/2015 09:52:47,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treated,NA,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 09:58:55,1738648894,9/15/2015 09:58:26,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS],[TREATS],treated,N/A,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 09:59:52,1738649129,9/15/2015 09:59:30,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treated with,N/A,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 10:03:46,1738650286,9/15/2015 10:01:52,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[SIDE_EFFECT],[SIDE_EFFECT],effects,N/a,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 10:04:50,1738650530,9/15/2015 10:04:27,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],treated,N/A,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 10:05:45,1738650810,9/15/2015 10:04:37,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[OTHER],[OTHER],treated with,N/A,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 10:11:25,1738652502,9/15/2015 10:09:26,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],CONGESTIVE HEART FAILURE are treated with DIGITALIS and diuretic agents.,they are related,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 10:13:34,1738653036,9/15/2015 10:13:14,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],treated with,n/a,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660745,9/15/2015 10:23:50,1738655750,9/15/2015 10:23:18,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],treated,N/A,50,96,74,73,105,RO-may_prevent,820325-FS1,Salutary effects can be expected in patients with CONGESTIVE HEART FAILURE who are treated with DIGITALIS and diuretic agents.,CONGESTIVE HEART FAILURE,DIGITALIS
788660746,9/15/2015 10:36:22,1738658713,9/15/2015 10:36:08,false,elite,1.0,30659677,USA,"","",162.252.172.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relate,N/A,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 10:37:23,1738659027,9/15/2015 10:36:57,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],attempt to relate,N/A,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 10:39:20,1738659549,9/15/2015 10:38:53,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"experience, and",n/a,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 10:40:51,1738660018,9/15/2015 10:40:07,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],attempt to relate,N/A,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 10:41:51,1738660269,9/15/2015 10:41:39,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[LOCATION],[LOCATION],IN,N/A,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 10:42:57,1738660549,9/15/2015 10:40:31,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[SIDE_EFFECT],[SIDE_EFFECT],residing,Side effict,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 10:49:14,1738661994,9/15/2015 10:48:43,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[PART_OF],[PART_OF],FLUORIDE CONCENTRATION IN ENAMEL CARIES,N/a,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 10:50:19,1738662263,9/15/2015 10:50:07,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],study,N/A,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 11:00:23,1738664508,9/15/2015 11:00:02,false,elite,1.0,30659615,USA,"","",162.250.145.234,[LOCATION],[LOCATION],IN,N/A,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 11:03:10,1738665115,9/15/2015 11:01:27,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[PART_OF],[PART_OF],IN,N/A,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 11:17:16,1738669671,9/15/2015 11:16:37,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",FLUORIDE CONCENTRATION IN ENAMEL CARIES,N/a,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 11:21:55,1738672189,9/15/2015 11:20:32,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[PREVENTS],[PREVENTS],attempt to relate,N/A,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 11:25:09,1738674055,9/15/2015 11:24:34,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[LOCATION],[LOCATION],FLUORIDE CONCENTRATION IN ENAMEL CARIES,N/A,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 11:34:07,1738678690,9/15/2015 11:33:58,false,elite,1.0,33798502,USA,VA,Manassas,207.244.86.193,[CONTRAINDICATES],[CONTRAINDICATES],FLUORIDE,N/A,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660746,9/15/2015 11:49:51,1738685818,9/15/2015 11:49:24,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relate,n/a,90,57,97,95,89,RO-may_prevent,820204-FS1,"The object of the present study was an attempt to relate FLUORIDE CONCENTRATION IN ENAMEL CARIES experience, and the degree of fluorosis in a community residing in an area with a high level of fluoride.",CARIES,FLUORIDE CONCENTRATION IN ENAMEL
788660747,9/15/2015 09:30:36,1738640685,9/15/2015 09:30:12,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],referred FOR TREATMENT,N/A,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 09:51:36,1738647037,9/15/2015 09:51:12,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[OTHER],[OTHER],UNDERWENT,n/a,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 09:52:48,1738647346,9/15/2015 09:50:41,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[NONE],[NONE],N/A,THYROID treated before  HYPOTHYROIDISM,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 09:57:30,1738648575,9/15/2015 09:56:37,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was referred FOR TREATMENT,N/A,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 09:58:25,1738648789,9/15/2015 09:58:02,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],TREATMENT,n/a,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 10:06:45,1738651078,9/15/2015 10:06:17,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],UNDERWENT RADIOABLATION,N/A,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 10:10:56,1738652352,9/15/2015 10:09:50,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID,N/A,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 10:13:07,1738652916,9/15/2015 10:11:43,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[SIDE_EFFECT] [MANIFESTATION],"[MANIFESTATION]
[SIDE_EFFECT]",AFTER SHE UNDERWENT,N/A,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 10:13:33,1738653035,9/15/2015 10:13:17,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],TREATMENT,N/A,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 10:19:34,1738654595,9/15/2015 10:19:19,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],TREATMENT,N/a,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 10:21:36,1738655100,9/15/2015 10:20:30,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[SYMPTOM],[SYMPTOM],AFTER SHE UNDERWENT RADIOABLATION OF THE,N/A,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 10:24:16,1738655876,9/15/2015 10:23:08,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],FOR TREATMENT HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE,prevent,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 10:24:46,1738656033,9/15/2015 10:24:08,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[CAUSES],[CAUSES],HYPOTHYROIDISM RADIOABLATION OF THE THYROID,N/A,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 10:27:32,1738656601,9/15/2015 10:27:19,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],TREATMENT,N/A,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660747,9/15/2015 10:32:56,1738657926,9/15/2015 10:32:47,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],TREATMENT,N/A,51,103,82,101,142,RO-may_prevent,820291-FS1,A woman in her 24th week of gestation was referred FOR TREATMENT OF HYPOTHYROIDISM AFTER SHE UNDERWENT RADIOABLATION OF THE THYROID DURING THE 13th week of gestation.,HYPOTHYROIDISM,THYROID
788660748,9/15/2015 10:38:14,1738659250,9/15/2015 10:38:03,false,elite,1.0,30659677,USA,"","",162.252.172.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],increasing,N/A,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 10:40:05,1738659822,9/15/2015 10:39:33,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[LOCATION],[LOCATION],exposure of the human thyroid,N/A,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 10:41:50,1738660262,9/15/2015 10:41:38,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"THYROIDitis, HYPOTHYROIDISM",n/a,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 10:43:48,1738660727,9/15/2015 10:43:35,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"radiation,",N/A,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 10:46:43,1738661460,9/15/2015 10:45:08,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[LOCATION],[LOCATION],developed,N/A,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 10:49:13,1738661982,9/15/2015 10:48:02,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[CAUSES],[CAUSES],risk acute,Causr,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 10:52:19,1738662703,9/15/2015 10:52:08,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],developed,N/A,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 10:53:27,1738663003,9/15/2015 10:52:49,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[NONE],[NONE],N/a,Two unrelated conditions.,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 11:03:15,1738665121,9/15/2015 11:02:59,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],developed,N/A,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 11:21:57,1738672186,9/15/2015 11:20:47,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],risk estimates have been developed for,N/A,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 11:22:36,1738672585,9/15/2015 11:21:44,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[PART_OF],[PART_OF],HYPOTHYROIDISM thyroid,N/a,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 11:29:08,1738676355,9/15/2015 11:27:22,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[LOCATION],[LOCATION],following exposure of,N/A,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 11:32:13,1738678041,9/15/2015 11:30:59,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"THYROIDitis, HYPOTHYROIDISM",N/A,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 11:55:06,1738688143,9/15/2015 11:54:35,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPOTHYROIDISM,n/a,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660748,9/15/2015 12:12:49,1738693779,9/15/2015 12:12:00,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[CAUSES],[CAUSES],malignant,N/A,175,162,189,188,169,RO-may_prevent,820173-FS1,"Because of increasing concern over continuing medical and potential nonmedical exposure of the thyroid to radiation, risk estimates have been developed for acute THYROIDitis, HYPOTHYROIDISM and both benign and malignant thyroid nodules following exposure of the human thyroid to external and internal sources of ionizing radiation.",HYPOTHYROIDISM,THYROID
788660749,9/15/2015 09:32:39,1738641250,9/15/2015 09:32:21,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[PREVENTS],[PREVENTS],Reduced,N/A,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 09:54:45,1738647913,9/15/2015 09:54:20,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[PART_OF],[PART_OF],supplement,n/a,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:00:48,1738649323,9/15/2015 10:00:22,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[PREVENTS],[PREVENTS],Reduced,n/a,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:00:48,1738649324,9/15/2015 09:58:41,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],supplement,N/A,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:02:26,1738649819,9/15/2015 10:01:11,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],orally used as a supplement,N/A,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:09:11,1738651760,9/15/2015 10:08:50,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[PREVENTS],[PREVENTS],Reduced used as a supplement Corticosteroids,N/A,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:15:56,1738653732,9/15/2015 10:15:37,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],Reduced,N/A,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:16:59,1738653998,9/15/2015 10:15:41,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],Reduced INFLAMMATION,N/A,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:16:59,1738653999,9/15/2015 10:15:33,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[PREVENTS],[PREVENTS],Widely used as a supplement,N/A,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:21:33,1738655099,9/15/2015 10:21:08,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],used,N/a,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:26:45,1738656474,9/15/2015 10:26:03,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],used as a supplement,N/A,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:27:59,1738656718,9/15/2015 10:27:15,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],Reduced INFLAMMATION Diarrhea Corticosteroids (PREDNISONE METHYLPREDNISOLONE).,prevents,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:28:38,1738656858,9/15/2015 10:28:26,false,elite,1.0,30659754,USA,"","",162.250.145.204,[LOCATION],[LOCATION],after,N/A,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:33:36,1738658077,9/15/2015 10:33:23,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],assessment,N/A,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660749,9/15/2015 10:34:19,1738658264,9/15/2015 10:33:41,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],Reduced INFLAMMATION,N/A,584,653,596,595,682,RO-may_treat,820056-FS1,"Continuous epidural analgesia with 0.1% bupivacaine for 5 to 7 days  Active against peripheral mechanisms of neuropathic pain  Hypotension, bradycardia, heart block, cardiac arrhythmias, cardiac arrest, myocardial depression, seizures, nausea, paresthesias, burning at catheter site, pruritus, restlessness  Inpatient treatment, frequent assessment of vital signs and neurologic status necessary Vitamin C  Reduces lipid peroxidation, scavenges hydroxyl radicals, protects the capillary endothelium, and inhibits vascular permeability  500 mg orally for 50 days after injury  Reduced INFLAMMATION  Diarrhea  Widely used as a supplement Corticosteroids (PREDNISONE METHYLPREDNISOLONE).",INFLAMMATION,PREDNISONE METHYLPREDNISOLONE
788660750,9/15/2015 10:41:43,1738660212,9/15/2015 10:41:25,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],in spite of DICOUMAROL treatment.,N/A,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 10:43:00,1738660563,9/15/2015 10:42:46,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],"institution treatment, treatment.",n.a,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 10:44:44,1738660932,9/15/2015 10:44:32,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],"treatment,",N/A,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 10:50:51,1738662367,9/15/2015 10:50:04,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],treatment.,N/A,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 10:52:24,1738662726,9/15/2015 10:52:00,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],treatment.,Treat,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 10:53:21,1738662979,9/15/2015 10:53:09,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],"treatment,",N/A,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 10:56:00,1738663598,9/15/2015 10:55:46,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],treatment.,N/a,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 11:04:19,1738665397,9/15/2015 11:04:08,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],"treatment,",N/A,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 11:28:38,1738676133,9/15/2015 11:28:16,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment.,N/A,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 11:33:48,1738678659,9/15/2015 11:33:16,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatment.,N/A,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 11:36:42,1738679785,9/15/2015 11:35:53,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],VENOUS THROMBOSIS in spite of DICOUMAROL treatment.,N/A,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 11:57:14,1738688857,9/15/2015 11:56:56,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],treatment.,n/a,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 12:15:45,1738694745,9/15/2015 12:15:04,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment.,N/A,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 12:16:35,1738695134,9/15/2015 12:15:16,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],VENOUS THROMBOSIS,NONE,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660750,9/15/2015 12:31:12,1738700123,9/15/2015 12:30:34,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[CONTRAINDICATES],[CONTRAINDICATES],in spite of treatment.,N/A,55,146,72,71,156,RO-may_prevent,820178-FS1,"The patients in this material had had 2 20 episodes of VENOUS THROMBOSIS the most recent 5 years before the institution of treatment, in spite of DICOUMAROL treatment.",VENOUS THROMBOSIS,DICOUMAROL
788660751,9/15/2015 12:06:49,1738691577,9/15/2015 12:06:31,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],PROTECTIVE EFFECT,n/a,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 12:27:18,1738698806,9/15/2015 12:26:48,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[PREVENTS],[PREVENTS],PROTECTIVE,N/A,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 12:29:30,1738699488,9/15/2015 12:29:08,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],HYDROXYCHLOROQUINE,NONE,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 12:51:00,1738706313,9/15/2015 12:50:48,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",very good,very good,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 12:54:39,1738707129,9/15/2015 12:54:03,false,elite,1.0,28548715,USA,"","",38.95.108.245,[PREVENTS],[PREVENTS],PROTECTIVE,n/a,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 12:57:08,1738707823,9/15/2015 12:54:29,false,neodev,1.0,34081836,USA,CA,San Jose,173.245.65.34,[ASSOCIATED_WITH],[ASSOCIATED_WITH],active systemic lupus erythematosus PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV,active systemic lupus erythematosus PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 12:57:16,1738707872,9/15/2015 12:55:42,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[PREVENTS],[PREVENTS],PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV,n/a,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 12:58:18,1738708091,9/15/2015 12:57:49,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[TREATS] [PREVENTS] [NONE],"[TREATS]
[PREVENTS]
[NONE]",[DIAGNOSED_BY_TEST_OR_DRUG],N/A,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 12:59:05,1738708303,9/15/2015 12:58:47,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[PREVENTS],[PREVENTS],RENAL DAMAGE,none,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 12:59:46,1738708486,9/15/2015 12:59:05,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[NONE] [MANIFESTATION],"[MANIFESTATION]
[NONE]",N/A,N/A,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 13:14:28,1738712374,9/15/2015 13:13:59,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[PREVENTS],[PREVENTS],PROTECTIVE EFFECT,n/a,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 13:24:37,1738715723,9/15/2015 13:23:49,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[SIDE_EFFECT],[SIDE_EFFECT],PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE LUPUS NEPHRITIS LXV data,N/A,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 13:37:05,1738720750,9/15/2015 13:36:41,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[CAUSES],[CAUSES],patients with,n/a,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 13:52:38,1738724958,9/15/2015 13:51:45,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],LUPUS NEPHRITIS LXV,n/a,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660751,9/15/2015 14:02:17,1738727250,9/15/2015 14:01:14,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[PREVENTS],[PREVENTS],PROTECTIVE EFFECT,N/A,140,67,145,158,122,RO-may_treat,820057-FS1,of belimumab in patients with active systemic lupus erythematosus  PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE in patients with LUPUS NEPHRITIS LXV data from a multiethnic US cohort  A quality indicator set for systemic lupus erythematosus  British Medical Journal  Systemic lupus erythematosus  Circulation.,LUPUS NEPHRITIS LXV,PROTECTIVE EFFECT OF HYDROXYCHLOROQUINE ON RENAL DAMAGE
788660752,9/15/2015 13:03:19,1738709418,9/15/2015 13:03:10,false,neodev,1,33701549,USA,CA,San Jose,23.27.248.252,[CONTRAINDICATES] [IS_A] [NONE],"[CONTRAINDICATES]
[IS_A]
[NONE]",[PREVENTS],N/A,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 13:03:51,1738709560,9/15/2015 13:03:21,false,elite,1,28548715,USA,"","",38.95.108.245,[TREATS],[TREATS],thrombosis decreased ENDOGENOUS PLASMA,n/a,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 13:04:42,1738709758,9/15/2015 13:04:18,false,zoombucks,1,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],ANTITHROMBIN III DEFICIENCY,none,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 13:21:41,1738714634,9/15/2015 13:21:10,false,instagc,1,13581319,USA,IL,Trenton,208.70.36.12,[SYMPTOM],[SYMPTOM],family history,n/a,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 13:30:58,1738717518,9/15/2015 13:28:54,false,gifthulk,1,18666417,USA,PA,Meadville,24.101.32.13,[CAUSES],[CAUSES],decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS; exclude ANTITHROMBIN III DEFICIENCY,n/a,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 13:33:53,1738718272,9/15/2015 13:33:29,false,neodev,1,31743852,GBR,H9,London,77.89.149.62,[ASSOCIATED_WITH],[ASSOCIATED_WITH],decreased ENDOGENOUS PLASMA ANTITHROMBIN CONCENTRATIONS; 1 6 exclude acquired ANTITHROMBIN III DEFICIENCY,N/A,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 14:09:35,1738729112,9/15/2015 14:08:33,false,elite,1,30064988,GBR,G8,Huddersfield,92.29.158.223,[OTHER],[OTHER],Confirm,n/a,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 14:28:55,1738734682,9/15/2015 14:28:14,false,instagc,1,32352104,USA,ME,Bangor,74.75.63.81,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS; exclude acquired ANTITHROMBIN III DEFICIENCY,n/a,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 14:32:51,1738735687,9/15/2015 14:32:35,false,tremorgames,1,24449707,CAN,QC,Laval,96.20.14.148,[CAUSES],[CAUSES],acquired,N/A,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 14:42:58,1738738519,9/15/2015 14:42:45,false,neodev,1,33895262,USA,VA,Mclean,63.141.204.167,[PREVENTS] [LOCATION] [NONE],"[PREVENTS]
[LOCATION]
[NONE]",N/A,N/A,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 14:45:19,1738739218,9/15/2015 14:44:40,false,prodege,1,14848125,GBR,V8,Airdrie,86.151.77.161,[ASSOCIATED_WITH],[ASSOCIATED_WITH],clear family history of ENDOGENOUS PLASMA ANTITHROMBIN III,n/a,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 14:51:24,1738741007,9/15/2015 14:50:45,false,prodege,1,33753166,CAN,ON,Toronto,173.206.80.252,[ASSOCIATED_WITH],[ASSOCIATED_WITH],history decreased acquired,N/A,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 15:10:40,1738747807,9/15/2015 15:10:22,false,bitcoinget,1,21743413,USA,WA,Port Angeles,65.193.218.66,[OTHER],[OTHER],exclude,N/A,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 15:11:09,1738747981,9/15/2015 15:09:37,false,zoombucks,1,6744840,CAN,BC,Kelowna,174.4.58.160,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Confirm,N/A,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660752,9/15/2015 15:18:04,1738751241,9/15/2015 15:17:52,false,neodev,1,34431172,CAN,AB,Edmonton,208.123.223.129,[PREVENTS] [LOCATION] [NONE],"[PREVENTS]
[LOCATION]
[NONE]",no,no,194,115,221,220,164,RO-may_treat,820058-FS1,"2  Confirm congenital antithrombin III deficiency based on clear family history of venous thrombosis and decreased ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS;  1 ,   6   exclude acquired ANTITHROMBIN III DEFICIENCY",ANTITHROMBIN III DEFICIENCY,ENDOGENOUS PLASMA ANTITHROMBIN III CONCENTRATIONS
788660753,9/15/2015 09:25:18,1738639423,9/15/2015 09:24:39,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],Decrease tissue response to,N/A,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 09:37:45,1738643054,9/15/2015 09:37:05,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",Decrease,N/A,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 09:45:53,1738645517,9/15/2015 09:45:21,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[CONTRAINDICATES],[CONTRAINDICATES],inhibit,n/a,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 09:47:57,1738645987,9/15/2015 09:47:00,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],Decrease tissue response inhibit accumulation of,N/A,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 09:53:53,1738647704,9/15/2015 09:53:08,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],Decrease,n/a,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 09:58:47,1738648882,9/15/2015 09:57:48,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[PREVENTS],[PREVENTS],Decrease tissue response,N/A,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 10:01:30,1738649576,9/15/2015 10:01:01,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[SIDE_EFFECT],[SIDE_EFFECT],Decrease tissue response,N/A,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 10:05:43,1738650804,9/15/2015 10:04:49,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Decrease tissue response to,N/A,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 10:06:58,1738651153,9/15/2015 10:06:26,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],Decrease,N/A,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 10:08:49,1738651665,9/15/2015 10:07:33,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[ASSOCIATED_WITH],[ASSOCIATED_WITH],response,N/a,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 10:11:11,1738652435,9/15/2015 10:10:19,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[SYMPTOM],[SYMPTOM],Decrease tissue response inhibit accumulation inflammatory cells;,N/A,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 10:15:36,1738653632,9/15/2015 10:15:07,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],INFLAMMATION; inhibit TRIAMCINOLONE ACETONIDE,cure,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 10:17:38,1738654170,9/15/2015 10:16:33,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[NONE],[NONE],n/a,sentence seems incomplete,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 10:24:58,1738656056,9/15/2015 10:24:47,false,elite,1.0,30659754,USA,"","",162.250.145.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],accumulation,N/A,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660753,9/15/2015 10:31:51,1738657614,9/15/2015 10:30:41,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],Decrease,N/A,132,219,144,143,242,RO-may_treat,820059-FS1,Alleviates cystoid macular edema (tvml 137tvml ) Intravitreal corticosteroids: Triamcinolone acetonide  Decrease tissue response to INFLAMMATION; inhibit accumulation of inflammatory cells; inhibit lymphocyte function  TRIAMCINOLONE ACETONIDE 4 mg/0.1 mL  Reduction of anterior and intermediate uveitis.,INFLAMMATION,TRIAMCINOLONE ACETONIDE
788660754,9/15/2015 12:07:10,1738691732,9/15/2015 12:06:50,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],receiving,n/a,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 12:27:44,1738698956,9/15/2015 12:27:20,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[ASSOCIATED_WITH],[ASSOCIATED_WITH],accordance,N/A,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 12:30:23,1738699834,9/15/2015 12:29:31,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[SYMPTOM],[SYMPTOM],DUODENAL ULCER,NONE,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 12:51:14,1738706375,9/15/2015 12:51:00,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",very good,very good,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 12:55:36,1738707432,9/15/2015 12:54:41,false,elite,1.0,28548715,USA,"","",38.95.108.245,[SIDE_EFFECT] [ASSOCIATED_WITH],"[ASSOCIATED_WITH]
[SIDE_EFFECT]",accordance,n/a,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 12:58:34,1738708144,9/15/2015 12:57:17,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Fifty four patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial,n/a,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 12:58:37,1738708148,9/15/2015 12:57:51,false,neodev,1,34081836,USA,CA,San Jose,173.245.65.34,[TREATS],[TREATS],receiving RANITIDINE completed the trial in accordance,and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 12:58:36,1738708149,9/15/2015 12:58:20,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[TREATS] [ASSOCIATED_WITH] [PART_OF] [NONE],"[TREATS]
[ASSOCIATED_WITH]
[PART_OF]
[NONE]",[MANIFESTATION],N/A,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 12:59:22,1738708387,9/15/2015 12:59:06,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],RANITIDINE,none,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 13:01:47,1738709048,9/15/2015 12:59:46,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[NONE],[NONE],N/A,"text show that users in tiral used the drug, but remains silent on if it is a treatment. It's not explicit only implied",83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 13:14:41,1738712445,9/15/2015 13:14:29,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],receiving RANITIDINE,n/a,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 13:25:09,1738715891,9/15/2015 13:24:38,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],53 patients with DUODENAL ULCER (28 receiving RANITIDINE the trial,N/A,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 13:37:22,1738721126,9/15/2015 13:37:06,false,bitcoinget,1,31256687,USA,NY,Poughkeepsie,67.82.252.135,[CAUSES],[CAUSES],receiving,n/a,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 13:53:02,1738725077,9/15/2015 13:52:39,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DUODENAL ULCER (28 receiving RANITIDINE trial,n/a,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660754,9/15/2015 14:01:13,1738726933,9/15/2015 13:59:46,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],receiving RANITIDINE,I didn't select None,83,112,97,96,122,RO-may_prevent,820214-FS1,Fifty four patients with prepyloric (26 receiving ranitidine) and 53 patients with DUODENAL ULCER (28 receiving RANITIDINE completed the trial in accordance with the protocol.,DUODENAL ULCER,RANITIDINE
788660755,9/15/2015 10:36:52,1738658852,9/15/2015 10:36:40,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],cimetidine,N/A,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 10:37:55,1738659156,9/15/2015 10:37:39,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],safe and effective in healing,N/A,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 10:39:50,1738659730,9/15/2015 10:39:35,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],RANITIDINE effective GASTRIC ULCERS,n/a,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 10:41:43,1738660206,9/15/2015 10:41:15,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],safe effective,N/A,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 10:42:23,1738660391,9/15/2015 10:42:06,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],effective,N/A,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 10:44:17,1738660834,9/15/2015 10:43:47,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],healing,Treat,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 10:50:04,1738662200,9/15/2015 10:49:46,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],healing,N/a,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 10:50:47,1738662366,9/15/2015 10:50:34,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],prevention,N/A,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 11:01:17,1738664738,9/15/2015 11:01:05,false,elite,1.0,30659615,USA,"","",162.250.145.234,[PREVENTS],[PREVENTS],prevention,N/A,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 11:05:04,1738665600,9/15/2015 11:04:16,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],effective in healing,N/A,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 11:18:45,1738670224,9/15/2015 11:18:19,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],RANITIDINE effective healing GASTRIC ULCERS,N/a,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 11:22:57,1738672675,9/15/2015 11:22:25,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],effective in healing,N/A,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 11:26:44,1738674923,9/15/2015 11:26:02,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],RANITIDINE been shown safe effective healing duodenal GASTRIC ULCERS,N/A,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 11:51:39,1738686610,9/15/2015 11:50:16,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],effective in healing,n/a,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660755,9/15/2015 12:09:05,1738692286,9/15/2015 12:08:19,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[PREVENTS],[PREVENTS],prevention,N/A,91,0,105,104,10,RO-may_prevent,820338-FS1,RANITIDINE and cimetidine have been shown to be safe and effective in healing duodenal and GASTRIC ULCERS and in prevention of duodenal ulcer relapse.,GASTRIC ULCERS,RANITIDINE
788660756,9/15/2015 10:46:44,1738661475,9/15/2015 10:46:30,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treat,N/A,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 10:55:33,1738663520,9/15/2015 10:55:19,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treat,N/A,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 10:58:46,1738664130,9/15/2015 10:58:19,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],treat,Treat,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 11:00:51,1738664622,9/15/2015 11:00:39,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],treat,N/a,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 11:06:39,1738665941,9/15/2015 11:06:25,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treat,N/A,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 11:39:18,1738680843,9/15/2015 11:38:57,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],used to treat,N/A,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 11:41:13,1738681727,9/15/2015 11:40:29,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treat,N/A,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 11:42:49,1738682447,9/15/2015 11:42:30,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],used to treat,N/A,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 12:02:43,1738690364,9/15/2015 12:02:27,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],treat,n/a,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 12:23:24,1738697654,9/15/2015 12:23:08,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treat,N/A,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 12:24:04,1738697891,9/15/2015 12:23:20,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],TUBERCULOSIS,NONE,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 12:43:41,1738704278,9/15/2015 12:43:17,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",none,very good,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 12:45:46,1738704996,9/15/2015 12:44:55,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[TREATS],[TREATS],used to treat,N/A,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 12:47:37,1738705510,9/15/2015 12:46:50,false,elite,1.0,28548715,USA,"","",38.95.108.245,[TREATS],[TREATS],treat,n/a,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660756,9/15/2015 12:50:59,1738706310,9/15/2015 12:49:09,false,neodev,1.0,34081836,USA,CA,San Jose,173.245.65.34,[TREATS],[TREATS],essential drug used to treat,is an essential drug used to treat TUBERCULOSIS,51,0,63,62,9,RO-may_prevent,820219-FS1,ISONIAZID (INH) is an essential drug used to treat TUBERCULOSIS,TUBERCULOSIS,ISONIAZID
788660757,9/15/2015 09:38:02,1738643138,9/15/2015 09:37:48,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],"treatment,",N/A,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 09:55:37,1738648096,9/15/2015 09:55:12,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[PART_OF],[PART_OF],"treatment,",n/a,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:01:34,1738649593,9/15/2015 10:01:10,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],"treatment,",n/a,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:02:32,1738649865,9/15/2015 10:01:38,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],"treatment,",N/A,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:04:04,1738650378,9/15/2015 10:03:28,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],"in asthma treatment,",N/A,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:10:05,1738652022,9/15/2015 10:09:41,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS],[TREATS],"asthma treatment,",N/A,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:16:37,1738653937,9/15/2015 10:16:20,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],"treatment,",N/A,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:17:55,1738654233,9/15/2015 10:17:25,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],"treatment,",N/A,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:20:34,1738654852,9/15/2015 10:18:56,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[PREVENTS],[PREVENTS],"possess significant anti inflammatory effects,",N/A,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:22:26,1738655339,9/15/2015 10:21:59,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],"treatment,",N/a,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:28:29,1738656824,9/15/2015 10:27:34,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],"treatment,",N/A,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:29:10,1738657025,9/15/2015 10:28:54,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SIDE_EFFECT],[SIDE_EFFECT],"effects,",N/A,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:29:52,1738657202,9/15/2015 10:28:36,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NEDOCROMIL agonists ASTHMA.,cause,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:34:01,1738658193,9/15/2015 10:33:49,false,elite,1.0,30659677,USA,"","",162.252.172.126,[SIDE_EFFECT],[SIDE_EFFECT],"effects,",N/A,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660757,9/15/2015 10:34:34,1738658356,9/15/2015 10:34:20,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],"asthma treatment, NEDOCROMIL",N/A,253,82,70,258,92,RO-may_prevent,820180-FS1,"Of non steroidal agents that have well established positions in asthma treatment, NEDOCROMIL and cromolyn possess significant anti inflammatory effects, and theophylline and beta agonists possess some anti inflammatory effects of potential relevance to ASTHMA.",ASTHMA,NEDOCROMIL
788660758,9/15/2015 10:36:39,1738658776,9/15/2015 10:36:23,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],using,N/A,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 10:37:37,1738659086,9/15/2015 10:37:24,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],PAIN alleviation,N/A,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 10:39:35,1738659653,9/15/2015 10:39:20,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[SYMPTOM],[SYMPTOM],PAIN NAPROXEN,n/a,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 10:41:14,1738660118,9/15/2015 10:40:52,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],alleviation,N/A,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 10:42:05,1738660309,9/15/2015 10:41:53,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],studied,N/A,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 10:43:45,1738660710,9/15/2015 10:42:58,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[PART_OF],[PART_OF],effect of naproxen,Part,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 10:49:45,1738662142,9/15/2015 10:49:15,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],alleviation,N/a,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 10:50:33,1738662306,9/15/2015 10:50:21,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],studied,N/A,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 11:01:03,1738664653,9/15/2015 11:00:25,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],studied,N/A,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 11:04:14,1738665359,9/15/2015 11:03:12,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],alleviation,N/A,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 11:18:19,1738670089,9/15/2015 11:17:18,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],naproxen on PAIN alleviation,N/a,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 11:22:24,1738672425,9/15/2015 11:21:56,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",effect on alleviation,N/A,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 11:26:02,1738674545,9/15/2015 11:25:10,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],effect of naproxen on PAIN alleviation,N/A,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 11:50:15,1738685952,9/15/2015 11:49:52,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],effect on PAIN,n/a,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660758,9/15/2015 12:08:18,1738692037,9/15/2015 12:06:43,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],studied,N/A,37,107,41,40,115,RO-may_prevent,820181-FS1,The effect of naproxen (Naprosyn) on PAIN alleviation was studied in a double blind cross over trial using NAPROXEN and placebo.,PAIN,NAPROXEN
788660759,9/15/2015 10:37:18,1738659011,9/15/2015 10:37:06,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treatment,N/A,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 10:38:31,1738659290,9/15/2015 10:38:09,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],established treatment,N/A,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 10:40:34,1738659969,9/15/2015 10:40:20,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],ACYCLOVIR OROFACIAL HERPES SIMPLEX,n/a,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 10:42:50,1738660520,9/15/2015 10:42:38,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[PREVENTS],[PREVENTS],recurrent,N/A,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 10:43:12,1738660622,9/15/2015 10:42:20,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],therapeutic benefit,N/A,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 10:45:12,1738661058,9/15/2015 10:44:45,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],treatment,Treat,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 10:51:09,1738662440,9/15/2015 10:50:48,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],significant therapeutic benefit,N/a,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 10:51:16,1738662476,9/15/2015 10:51:01,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 11:02:04,1738664877,9/15/2015 11:01:32,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],recurrent,N/A,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 11:09:54,1738666715,9/15/2015 11:07:06,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],provide significant therapeutic benefit,N/A,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 11:19:50,1738671079,9/15/2015 11:19:16,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],ACYCLOVIR therapeutic benefit in OROFACIAL HERPES SIMPLEX,N/a,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 11:24:24,1738673718,9/15/2015 11:23:46,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],established treatment,N/A,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 11:28:30,1738676061,9/15/2015 11:27:38,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[PREVENTS],[PREVENTS],ACYCLOVIR significant therapeutic benefit recurrent OROFACIAL HERPES SIMPLEX,N/A,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 11:52:39,1738687032,9/15/2015 11:52:20,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],established treatment,n/a,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660759,9/15/2015 12:10:33,1738692690,9/15/2015 12:09:36,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],HERPES SIMPLEX,NONE,212,122,236,235,131,RO-may_prevent,820182-FS1,"As an established treatment of herpes simplex infection, intravenous, oral and to a lesser extent topical formulations of ACYCLOVIR provide significant therapeutic benefit in genital herpes simplex and recurrent OROFACIAL HERPES SIMPLEX",OROFACIAL HERPES SIMPLEX,ACYCLOVIR
788660760,9/15/2015 10:46:29,1738661442,9/15/2015 10:46:08,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],evidence,N/A,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 10:55:18,1738663393,9/15/2015 10:55:05,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"trials,",N/A,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 10:58:18,1738664018,9/15/2015 10:57:20,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],reduce,Treat,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 11:00:37,1738664553,9/15/2015 10:59:38,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[OTHER],[OTHER],chondroitin does not reduce pain in knee or hip osteoarthritis,N/a,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 11:06:23,1738665862,9/15/2015 11:06:08,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Keywords:,N/A,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 11:38:56,1738680767,9/15/2015 11:38:20,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER],[OTHER],OSTEOARTHRITIS,N/A,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 11:40:26,1738681337,9/15/2015 11:39:53,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],Keywords:,N/A,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 11:42:29,1738682316,9/15/2015 11:41:33,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS,N/A,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 12:02:26,1738690223,9/15/2015 12:00:47,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],"trials,",n/a,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 12:23:06,1738697553,9/15/2015 12:22:25,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[SIDE_EFFECT],[SIDE_EFFECT],reduce,N/A,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 12:23:18,1738697605,9/15/2015 12:21:54,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[PREVENTS],[PREVENTS],OSTEOARTHRITIS,NONE,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 12:43:16,1738704179,9/15/2015 12:42:20,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",none,very good,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 12:44:55,1738704735,9/15/2015 12:43:22,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[CONTRAINDICATES],[CONTRAINDICATES],does not reduce pain,N/A,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 12:48:20,1738705678,9/15/2015 12:46:23,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"Based on evidence from higher quality trials, does not reduce pain in CHONDROITIN SULFATES OSTEOARTHRITIS",n/a,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660760,9/15/2015 12:51:42,1738706507,9/15/2015 12:50:51,false,elite,1.0,28548715,USA,"","",38.95.108.245,[PREVENTS],[PREVENTS],reduce,n/a,198,162,217,215,197,RO-may_treat,820061-FS1,"Review: Based on evidence from higher quality trials, chondroitin does not reduce pain in knee or hip osteoarthritis  Rheumatology  About Star Ratings  Keywords: CHONDROITIN SULFATES OSTEOARTHRITIS HIP OSTEOARTHRITIS knee Pain  ACP Journal Club.",HIP OSTEOARTHRITIS,CHONDROITIN SULFATES OSTEOARTHRITIS
788660761,9/15/2015 12:54:37,1738707116,9/15/2015 12:54:21,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",very good,very good,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 13:02:04,1738709162,9/15/2015 13:01:39,false,elite,1.0,28548715,USA,"","",38.95.108.245,[PREVENTS],[PREVENTS],injection,n/a,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 13:02:22,1738709218,9/15/2015 13:02:10,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[PREVENTS] [TREATS] [CONTRAINDICATES] [NONE],"[TREATS]
[PREVENTS]
[CONTRAINDICATES]
[NONE]",[SIDE_EFFECT],N/A,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 13:03:25,1738709445,9/15/2015 13:03:01,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],CAPSAICIN,none,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 13:20:04,1738714064,9/15/2015 13:19:46,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],activity in spinothalamic tract neurons,n/a,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 13:20:55,1738714314,9/15/2015 13:19:51,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[CAUSES],[CAUSES],produced by an intradermal,N/A,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 13:23:17,1738715197,9/15/2015 13:21:30,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[CAUSES],[CAUSES],PAIN produced by CAPSAICIN,n/a,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 13:32:15,1738717777,9/15/2015 13:31:49,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],PAIN intradermal injection 100 micrograms of CAPSAICIN,N/A,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 14:07:28,1738728631,9/15/2015 14:07:09,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[CAUSES],[CAUSES],produced,n/a,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 14:19:16,1738731836,9/15/2015 14:18:23,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[OTHER] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[OTHER]",PAIN and neurogenic hyperalgesia produced by an intradermal injection of micrograms CAPSAICIN was investigated.,n/a,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 14:31:22,1738735342,9/15/2015 14:31:04,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[CAUSES],[CAUSES],produced by,N/A,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 14:41:30,1738738033,9/15/2015 14:41:11,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[PREVENTS] [NONE],"[PREVENTS]
[NONE]",A,A,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 14:47:08,1738739847,9/15/2015 14:46:30,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],contribution of CAPSAICIN,n/a,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 14:48:10,1738740192,9/15/2015 14:46:58,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",contribution produced by injection,N/A,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660761,9/15/2015 15:00:34,1738743622,9/15/2015 14:59:50,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,24.113.29.97,[SIDE_EFFECT],[SIDE_EFFECT],produced by an intradermal injection of,N/A,73,164,77,76,173,RO-may_prevent,820185-FS1,The contribution of activity in spinothalamic tract (STT) neurons to the PAIN and neurogenic hyperalgesia produced by an intradermal injection of 100 micrograms of CAPSAICIN was investigated.,PAIN,CAPSAICIN
788660762,9/15/2015 10:38:28,1738659285,9/15/2015 10:38:16,false,elite,1.0,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],reduce,N/A,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 10:40:36,1738659966,9/15/2015 10:40:06,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],reduce it more,N/A,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 10:42:06,1738660315,9/15/2015 10:41:52,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],INSULIN DIABETES,n/a,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 10:44:01,1738660781,9/15/2015 10:43:49,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[PREVENTS],[PREVENTS],reduce,N/A,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 10:48:03,1738661776,9/15/2015 10:46:44,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",reduce,N/A,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 10:50:26,1738662291,9/15/2015 10:49:14,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],reduce,Rrduce,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 10:52:35,1738662785,9/15/2015 10:52:20,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[PREVENTS],[PREVENTS],reduce,N/A,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 10:54:20,1738663186,9/15/2015 10:53:28,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],did reduce it more than,N/a,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 11:03:32,1738665184,9/15/2015 11:03:17,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],reduce,N/A,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 11:24:25,1738673713,9/15/2015 11:22:00,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[PREVENTS],[PREVENTS],reduce in patients with,N/A,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 11:29:51,1738676750,9/15/2015 11:29:08,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],reduce,N/A,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 11:33:17,1738678320,9/15/2015 11:32:14,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],SC INSULIN reduce it more TYPE DIABETES,N/A,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 11:55:24,1738688191,9/15/2015 11:55:07,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],reduce,n/a,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 12:14:32,1738694355,9/15/2015 12:12:51,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],reduce,N/A,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660762,9/15/2015 12:17:48,1738695846,9/15/2015 12:16:36,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[PREVENTS],[PREVENTS],INSULIN,NONE,286,174,228,300,184,RO-may_treat,820066-FS1,"Outcomes:  Change in hemoglobin A 1c  (HbA 1c ) level, proportion of patients achieving HbA 1c  level   MAIN RESULTS  Inhaled insulin did not reduce HbA 1c  level as much as SC INSULIN in patients with type 1 and type 2 diabetes but did reduce it more than oral agents in patients with TYPE 2 DIABETES (Table.",TYPE 2 DIABETES,SC INSULIN
788660763,9/15/2015 09:39:35,1738643809,9/15/2015 09:39:02,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],dose inhaled,N/A,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 09:56:39,1738648338,9/15/2015 09:56:17,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[CONTRAINDICATES],[CONTRAINDICATES],action plans,n/a,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:02:38,1738649893,9/15/2015 10:02:13,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],for,n/a,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:05:55,1738650852,9/15/2015 10:05:19,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:07:11,1738651207,9/15/2015 10:06:23,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],for long term control of,N/A,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:11:34,1738652513,9/15/2015 10:10:58,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",effects of,N/A,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:18:03,1738654259,9/15/2015 10:17:42,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],effects,N/A,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:20:01,1738654739,9/15/2015 10:19:29,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],for,N/A,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:23:23,1738655625,9/15/2015 10:22:42,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],NEDOCROMIL SODIUM for chronic asthma,N/A,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:25:08,1738656126,9/15/2015 10:24:39,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],medication,N/a,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:29:53,1738657206,9/15/2015 10:29:40,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CAUSES],[CAUSES],plans,N/A,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:31:25,1738657538,9/15/2015 10:30:32,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],action plans,N/A,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:32:16,1738657728,9/15/2015 10:31:35,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[PREVENTS],[PREVENTS],Asthma Cochrane NEDOCROMIL SODIUM,it is real,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:34:43,1738658382,9/15/2015 10:34:29,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],asthma:,N/A,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660763,9/15/2015 10:35:24,1738658492,9/15/2015 10:34:59,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],action plans for asthma in children NEDOCROMIL SODIUM for chronic asthma,N/A,630,218,254,643,235,RO-may_prevent,820220-FS1,Asthma genetics  Rapid effects of inhaled corticosteroids in acute asthma: an evidence based evaluation  Clinical Evidence  Asthma  Cochrane Database of Systematic Reviews  Written action plans for asthma in children  NEDOCROMIL SODIUM for chronic asthma in children  Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma  Ketotifen alone or as additional medication for long term control of asthma and wheeze in children  Oral xanthines as maintenance treatment for asthma in children  Addition of long acting beta2 agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for CHRONIC ASTHMA in adults and children  Addition of inhaled long.,CHRONIC ASTHMA,NEDOCROMIL SODIUM
788660764,9/15/2015 09:22:17,1738638676,9/15/2015 09:21:03,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[PREVENTS],[PREVENTS],eliminated evoked by,N/A,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 09:24:12,1738639085,9/15/2015 09:22:52,false,neodev,1.0,30627835,GBR,D8,Bishop Auckland,217.44.84.223,[SYMPTOM],[SYMPTOM],evoked by,N/A,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 09:27:35,1738639888,9/15/2015 09:26:30,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",eliminated,N/A,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 09:40:32,1738644034,9/15/2015 09:38:45,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],evoked by,N/A,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 09:43:08,1738644745,9/15/2015 09:42:11,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[MANIFESTATION],[MANIFESTATION],evoked by,n/a,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 09:50:54,1738646840,9/15/2015 09:50:15,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[CAUSES],[CAUSES],evoked by,none,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 09:52:45,1738647345,9/15/2015 09:51:39,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[CAUSES],[CAUSES],evoked by,NA,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 09:58:24,1738648790,9/15/2015 09:57:58,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[CAUSES],[CAUSES],evoked,N/A,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 09:59:29,1738649012,9/15/2015 09:58:54,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[CAUSES],[CAUSES],evoked by,N/A,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 09:59:48,1738649117,9/15/2015 09:57:48,false,neodev,1.0,18703384,GBR,T5,Aberdeen,151.231.237.211,[SIDE_EFFECT],[SIDE_EFFECT],evoked by,N/A,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 10:01:51,1738649673,9/15/2015 09:59:55,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[CAUSES],[CAUSES],evoked,N/a,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 10:04:26,1738650449,9/15/2015 10:02:11,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[CAUSES],[CAUSES],evoked,N/A,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 10:04:36,1738650482,9/15/2015 10:03:50,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[CAUSES],[CAUSES],evoked by,N/A,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 10:09:25,1738651799,9/15/2015 10:06:50,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",PAIN AND NEUROGENIC INFLAMMATION INTRADERMAL INJECTION OF CAPSAICIN,treat,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660764,9/15/2015 10:13:13,1738652945,9/15/2015 10:12:26,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[CAUSES],[CAUSES],evoked by,n/a,818,861,822,849,900,RO-may_prevent,820341-FS1,"Screening of a library of trimers of N alkylglycines resulted in the identification of two molecules referred to as DD161515 [N [2 (2 (N methylpyrrolidinyl)ethyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] and DD191515 [[N [3 (N,N diethylamino)propyl]glycyl] [N [2,4 dichlorophenethyl]glycyl] N (2,4 dichlorophenethyl)glycinamide] that selectively block VR1 channel activity with micromolar efficacy, rivaling that characteristic of vanilloid related inhibitors. These compounds appear to be noncompetitive VR1 antagonists that recognize a receptor site distinct from that of capsaicin. Intraperitoneal administration of both trialkylglycines into mice significantly attenuated thermal nociception as measured in the hot plate test. It is noteworthy that these compounds eliminated PAIN AND NEUROGENIC INFLAMMATION evoked by INTRADERMAL INJECTION OF CAPSAICIN INTO the animal hindpaw, as well as the thermal hyperalgesia induced by tissue irritation with nitrogen mustard. In contrast, responses to mechanical stimuli were not modified by either compound. Modulation of sensory nerve fibers excitability appears to underlie the peptoid analgesic activity. Collectively, these results indicate that blockade of VR1 activity attenuates chemical and thermal nociception and hyperalgesia, supporting the tenet that this ionotropic receptor contributes to chemical and thermal sensitivity and pain perception in vivo.",PAIN AND NEUROGENIC INFLAMMATION,INTRADERMAL INJECTION OF CAPSAICIN INTO
788660765,9/15/2015 10:47:27,1738661614,9/15/2015 10:47:14,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 10:56:22,1738663704,9/15/2015 10:56:08,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 11:00:26,1738664526,9/15/2015 10:59:51,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,Associate with,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 11:02:09,1738664895,9/15/2015 11:01:52,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],treatment,N/a,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 11:07:37,1738666112,9/15/2015 11:07:25,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 11:40:23,1738681315,9/15/2015 11:40:03,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],treatment of,N/A,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 11:44:30,1738683188,9/15/2015 11:42:59,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],treatment of,N/A,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 11:44:50,1738683359,9/15/2015 11:44:26,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],prolonged treatment,N/A,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 12:05:34,1738691195,9/15/2015 12:05:18,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],treatment with,n/a,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 12:25:01,1738698120,9/15/2015 12:24:42,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],treatment,N/A,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 12:26:23,1738698512,9/15/2015 12:26:02,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],GVHD,NONE,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 12:46:28,1738705192,9/15/2015 12:45:33,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",none,very good,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 12:51:35,1738706475,9/15/2015 12:50:44,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[TREATS],[TREATS],treatment,N/A,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 12:52:10,1738706605,9/15/2015 12:51:43,false,elite,1.0,28548715,USA,"","",38.95.108.245,[TREATS],[TREATS],treatment,n/a,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660765,9/15/2015 12:52:49,1738706730,9/15/2015 12:51:45,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],treatment of GVHD CYCLOSPORINE AND PREDNISONE.,n/a,102,112,106,105,139,RO-may_prevent,820348-FS1,Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with CYCLOSPORINE AND PREDNISONE.,GVHD,CYCLOSPORINE AND PREDNISONE
788660766,9/15/2015 10:47:41,1738661691,9/15/2015 10:47:29,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],taken,N/A,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 10:56:43,1738663760,9/15/2015 10:56:23,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[SIDE_EFFECT],[SIDE_EFFECT],enhance,N/A,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 11:01:08,1738664694,9/15/2015 11:00:28,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],enhance,Associate,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 11:02:52,1738665037,9/15/2015 11:02:11,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],when taken orally by patients with,N/a,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 11:07:51,1738666224,9/15/2015 11:07:39,false,elite,1.0,30659615,USA,"","",162.250.145.234,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],taken,N/A,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 11:40:55,1738681537,9/15/2015 11:40:24,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],taken by patients with,N/A,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 11:45:10,1738683560,9/15/2015 11:44:33,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",when taken orally by patients with,N/A,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 11:46:15,1738684132,9/15/2015 11:44:58,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS] [MANIFESTATION],"[TREATS]
[MANIFESTATION]",enhance bioavailability GANCICLOVIR when taken by patients with CYTOMEGALOVIRUS INFECTION,N/A,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 12:05:55,1738691287,9/15/2015 12:05:35,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],taken orally,n/a,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 12:25:32,1738698244,9/15/2015 12:25:03,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],orally,N/A,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 12:26:59,1738698695,9/15/2015 12:26:24,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],GANCICLOVIR,NONE,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 12:46:49,1738705341,9/15/2015 12:46:29,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",none,very good,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 12:52:39,1738706695,9/15/2015 12:52:11,false,elite,1.0,28548715,USA,"","",38.95.108.245,[PREVENTS],[PREVENTS],orally,n/a,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 12:53:22,1738706889,9/15/2015 12:51:35,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[NONE],[NONE],n/a,The relationship is actually between valganciclovir and GANCICLOVIR,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660766,9/15/2015 12:53:41,1738706927,9/15/2015 12:52:05,false,neodev,1.0,34081836,USA,CA,San Jose,173.245.65.34,[TREATS],[TREATS],shown to enhance the bioavailability of GANCICLOVIR,has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION,164,117,189,188,128,RO-may_prevent,820228-FS1,"In clinical trials, valganciclovir, the valyl ester of ganciclovir, has been shown to enhance the bioavailability of GANCICLOVIR when taken orally by patients with CYTOMEGALOVIRUS INFECTION",CYTOMEGALOVIRUS INFECTION,GANCICLOVIR
788660767,9/15/2015 12:53:35,1738706906,9/15/2015 12:53:21,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[NONE],[NONE],very good,very good,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 13:00:01,1738708506,9/15/2015 12:59:33,false,elite,1.0,28548715,USA,"","",38.95.108.245,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",schizophrenia;,n/a,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 13:01:29,1738708900,9/15/2015 13:01:16,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[TREATS] [LOCATION] [CONTRAINDICATES] [PART_OF] [OTHER] [NONE],"[TREATS]
[LOCATION]
[CONTRAINDICATES]
[PART_OF]
[OTHER]
[NONE]",[SIDE_EFFECT],N/A,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 13:01:56,1738709062,9/15/2015 13:01:37,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],OLANZAPINE,none,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 13:13:06,1738712004,9/15/2015 13:11:06,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS] [SIDE_EFFECT],"[TREATS]
[SIDE_EFFECT]",tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from younger patients with schizophrenia.,n/a,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 13:14:21,1738712372,9/15/2015 13:11:37,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[OTHER],[OTHER],may differ from,N/A,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 13:18:36,1738713649,9/15/2015 13:18:09,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],Safety,n/a,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 13:30:17,1738717350,9/15/2015 13:29:40,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[SIDE_EFFECT],[SIDE_EFFECT],tolerability profile OLANZAPINE geriatric patients with DEMENTIA RELATED PSYCHOSIS,N/A,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 14:06:04,1738728286,9/15/2015 14:05:22,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],tolerability profile,n/a,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 14:14:38,1738730511,9/15/2015 14:14:05,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],OLANZAPINE geriatric with DEMENTIA RELATED PSYCHOSIS may differ from younger patients schizophrenia.,n/a,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 14:30:07,1738735086,9/15/2015 14:29:45,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],of in patients with,N/A,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 14:40:01,1738737556,9/15/2015 14:39:45,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[TREATS] [NONE],"[TREATS]
[NONE]",A,A,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 14:43:54,1738738839,9/15/2015 14:43:17,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],in geriatric patients with DEMENTIA RELATED PSYCHOSIS,n/a,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 14:44:46,1738739063,9/15/2015 14:43:15,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[TREATS],[TREATS],tolerability,N/A,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660767,9/15/2015 14:47:50,1738740032,9/15/2015 14:45:32,false,clixsense,1.0,24204845,GBR,L3,Rotherham,86.162.168.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS,N/A,275,237,301,300,247,RO-may_treat,820071-FS1,"Safety and efficacy not established in children   1 ,   35  Geriatric Use  Safety in patients ≥65 years of age with schizophrenia does not appear to differ from that in younger adults with schizophrenia; however, tolerability profile of OLANZAPINE in geriatric patients with DEMENTIA RELATED PSYCHOSIS may differ from that in younger patients with schizophrenia.",DEMENTIA RELATED PSYCHOSIS,OLANZAPINE
788660768,9/15/2015 13:03:52,1738709565,9/15/2015 13:03:41,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[CAUSES] [MANIFESTATION] [NONE],"[CAUSES]
[MANIFESTATION]
[NONE]",[PREVENTS],N/A,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 13:04:55,1738709835,9/15/2015 13:04:33,false,elite,1.0,28548715,USA,"","",38.95.108.245,[PREVENTS],[PREVENTS],effective,n/a,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 13:05:24,1738709921,9/15/2015 13:05:09,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ESTROGEN,none,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 13:22:23,1738714874,9/15/2015 13:22:04,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],"did not find ESTROGEN effective,",n/a,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 13:33:16,1738718104,9/15/2015 13:32:00,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"placebo controlled trial for HOT FLASHES did not find ESTROGEN to be effective,",n/a,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 13:34:56,1738718448,9/15/2015 13:34:28,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],"HOT FLASHES did not find ESTROGEN effective,",N/A,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 14:11:00,1738729503,9/15/2015 14:10:33,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[OTHER],[OTHER],"not effective,",n/a,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 14:30:05,1738735081,9/15/2015 14:29:30,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"placebo controlled trial HOT FLASHES did not find ESTROGEN effective,",n/a,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 14:33:29,1738735847,9/15/2015 14:33:05,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[NONE],[NONE],N/A,Estrogen is not effective for hot flashes.,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 14:53:18,1738741450,9/15/2015 14:52:18,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[TREATS],[TREATS],"effective effective,",N/A,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 15:11:45,1738748277,9/15/2015 15:11:12,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,65.193.218.66,[OTHER],[OTHER],"did not find to be effective,",N/A,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 15:14:24,1738749538,9/15/2015 15:13:28,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],"effective,",N/A,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 15:18:34,1738751598,9/15/2015 15:18:20,false,neodev,1.0,34431172,CAN,AB,Edmonton,208.123.223.129,[NONE] [SYMPTOM] [LOCATION],"[LOCATION]
[SYMPTOM]
[NONE]",no,no,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 15:58:44,1738764901,9/15/2015 15:56:52,false,clixsense,1.0,32053717,GBR,"","",51.174.76.80,[SIDE_EFFECT],[SIDE_EFFECT],"did not find be effective,",there is relation!,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660768,9/15/2015 16:02:55,1738766889,9/15/2015 16:02:17,false,instagc,1.0,33058612,USA,IL,Glenview,162.229.106.229,[NONE],[NONE],N/A,There are really no words to link the two together. If it were estrogen to hot flashes that would be easier.,75,100,86,85,108,RO-may_treat,820073-FS1,"The 1 placebo controlled trial that found black cohosh to be effective for HOT FLASHES did not find ESTROGEN to be effective, which casts doubt on the study's validity.",HOT FLASHES,ESTROGEN
788660769,9/15/2015 10:45:11,1738661051,9/15/2015 10:44:53,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[TREATS],[TREATS],induce its,n/a,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 10:45:39,1738661178,9/15/2015 10:45:26,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],induce,N/A,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 10:53:57,1738663110,9/15/2015 10:52:44,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[CAUSES],[CAUSES],induce,N/A,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 10:54:34,1738663223,9/15/2015 10:54:21,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 10:56:09,1738663637,9/15/2015 10:55:02,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[OTHER],[OTHER],seedlings.,Other,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 10:58:42,1738664119,9/15/2015 10:58:20,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/a,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 11:05:25,1738665676,9/15/2015 11:05:06,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 11:35:28,1738679251,9/15/2015 11:33:26,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],and also induce,N/A,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 11:37:11,1738680064,9/15/2015 11:36:13,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER],[OTHER],and,N/A,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 11:40:01,1738681131,9/15/2015 11:39:25,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DEHYDRATION and SALT STRESS,N/A,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 11:59:47,1738689557,9/15/2015 11:59:27,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 12:20:35,1738696747,9/15/2015 12:20:04,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[SIDE_EFFECT],[SIDE_EFFECT],DEHYDRATION,NONE,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 12:20:55,1738696846,9/15/2015 12:20:24,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[SIDE_EFFECT],[SIDE_EFFECT],induce,N/A,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 12:38:36,1738702873,9/15/2015 12:37:04,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[PREVENTS] [DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION] [SIDE_EFFECT] [PART_OF] [NONE],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[SIDE_EFFECT]
[PART_OF]
[NONE]",none,very very good,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660769,9/15/2015 12:40:23,1738703437,9/15/2015 12:37:44,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[NONE],[NONE],n/a,Although the words could be seen as [ASSOCIATED] The text is not explicit about such a relation,0,16,11,10,27,RO-may_prevent,820194-FS1,DEHYDRATION and SALT STRESS also induce its transcription and enzymatic activity in seedlings.,DEHYDRATION,SALT STRESS
788660770,9/15/2015 12:35:36,1738701788,9/15/2015 12:35:17,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],GASTRIC ULCERS,NONE,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 12:52:48,1738706728,9/15/2015 12:52:36,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[NONE],[NONE],very good,very good,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 12:58:42,1738708170,9/15/2015 12:58:22,false,elite,1.0,28548715,USA,"","",38.95.108.245,[TREATS],[TREATS],treatment,n/a,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 13:00:39,1738708728,9/15/2015 13:00:26,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[DIAGNOSE_BY_TEST_OR_DRUG] [PART_OF] [MANIFESTATION] [SIDE_EFFECT] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]
[SIDE_EFFECT]
[PART_OF]
[NONE]",[TREATS],N/A,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 13:01:06,1738708836,9/15/2015 13:00:52,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],RANITIDINE,none,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 13:09:06,1738710905,9/15/2015 13:07:54,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]","results of trial suggest that, in treatment of GASTRIC ULCERS RANITIDINE is more effective",n/a,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 13:09:44,1738711110,9/15/2015 13:08:37,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[TREATS],[TREATS],administration of,N/A,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 13:17:35,1738713358,9/15/2015 13:16:45,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],evening administration,n/a,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 13:28:45,1738717031,9/15/2015 13:28:24,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],treatment GASTRIC ULCERS administration of RANITIDINE,N/A,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 13:39:36,1738722014,9/15/2015 13:39:27,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[TREATS],[TREATS],treatment,n/a,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 14:04:45,1738727932,9/15/2015 14:04:29,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],treatment,n/a,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 14:11:53,1738729693,9/15/2015 14:11:28,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],treatment of GASTRIC ULCERS RANITIDINE 300 mg more effective than other modes of ingestion.,n/a,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 14:28:49,1738734677,9/15/2015 14:28:08,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],treatment administration of,N/A,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 14:39:15,1738737318,9/15/2015 14:38:58,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES] [NONE],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[NONE]",A,A,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660770,9/15/2015 14:41:01,1738737856,9/15/2015 14:39:03,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[TREATS],[TREATS],treatment administration,N/A,60,111,74,73,121,RO-may_prevent,820195-FS1,"The results of this trial suggest that, in the treatment of GASTRIC ULCERS the early evening administration of RANITIDINE 300 mg is more effective than other modes of ingestion.",GASTRIC ULCERS,RANITIDINE
788660771,9/15/2015 10:35:51,1738658579,9/15/2015 10:35:40,false,elite,1.0,30659677,USA,"","",162.252.172.126,[CAUSES],[CAUSES],heartburn,N/A,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 10:36:25,1738658722,9/15/2015 10:36:09,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],relief for heartburn,N/A,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 10:38:39,1738659360,9/15/2015 10:38:26,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[SYMPTOM] [TREATS],"[TREATS]
[SYMPTOM]",HEARTBURN OMEPRAZOLE,n/a,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 10:38:50,1738659437,9/15/2015 10:38:21,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],more effective and faster relief,N/A,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 10:38:58,1738659455,9/15/2015 10:37:40,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[CAUSES],[CAUSES],Lansoprazole,Causr,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 10:41:24,1738660172,9/15/2015 10:41:12,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],effective,N/A,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 10:48:08,1738661780,9/15/2015 10:47:36,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],relief,N/a,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 10:49:52,1738662174,9/15/2015 10:49:35,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],effective,N/A,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 10:59:41,1738664354,9/15/2015 10:59:29,false,elite,1.0,30659615,USA,"","",162.250.145.234,[SIDE_EFFECT],[SIDE_EFFECT],effective,N/A,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 11:00:09,1738664469,9/15/2015 10:58:34,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],Keywords:,N/A,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 11:15:42,1738668895,9/15/2015 11:14:55,false,instagc,1.0,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],relief for heartburn than omeprazole,N/a,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 11:17:02,1738669563,9/15/2015 11:16:22,false,fusioncash,1,21457135,USA,FL,Orlando,71.47.115.162,[TREATS],[TREATS],provided effective faster relief,N/A,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 11:19:07,1738670513,9/15/2015 11:17:49,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],effective relief,N/A,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 11:23:30,1738673108,9/15/2015 11:22:32,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],effective faster relief heartburn,N/A,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660771,9/15/2015 11:33:31,1738678493,9/15/2015 11:32:09,false,elite,1.0,33798502,USA,VA,Manassas,207.244.86.193,[TREATS],[TREATS],OMEPRAZOLE,N/A,135,158,144,143,168,RO-may_treat,820074-FS1,Lansoprazole provided more effective and faster relief for heartburn than did omeprazole in erosive esophagitis  Keywords: Esophagitis HEARTBURN Lansoprazole OMEPRAZOLE  ACP Journal Club.,HEARTBURN,OMEPRAZOLE
788660772,9/15/2015 09:32:01,1738641037,9/15/2015 09:31:31,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[LOCATION],[LOCATION],insertion of the,N/A,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 09:53:02,1738647432,9/15/2015 09:52:37,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were prepared by,n/a,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 09:57:07,1738648447,9/15/2015 09:55:26,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[CAUSES],[CAUSES],insertion,N/A,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 10:00:03,1738649167,9/15/2015 09:59:19,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were prepared,n/a,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 10:00:36,1738649284,9/15/2015 09:59:50,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],were prepared by insertion,N/A,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 10:08:27,1738651558,9/15/2015 10:07:53,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],insertion of,N/A,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 10:14:39,1738653366,9/15/2015 10:13:20,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[PART_OF],[PART_OF],viruses were prepared by insertion of the HEPATITIS B SURFACE,N/A,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 10:15:09,1738653482,9/15/2015 10:14:36,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[SIDE_EFFECT],[SIDE_EFFECT],were prepared by,N/A,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 10:15:17,1738653519,9/15/2015 10:14:45,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[LOCATION],[LOCATION],region,N/A,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 10:17:18,1738654063,9/15/2015 10:15:19,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prepared,N/a,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 10:24:47,1738656041,9/15/2015 10:23:35,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],were prepared by,N/A,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 10:26:42,1738656473,9/15/2015 10:25:57,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[PREVENTS],[PREVENTS],"ADENOVIRUS (AD), HEPATITIS B RECOMBINANT HEP HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE",prevent it,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 10:27:08,1738656524,9/15/2015 10:25:42,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[CAUSES],[CAUSES],prepared by insertion of,N/A,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 10:28:11,1738656767,9/15/2015 10:27:58,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SYMPTOM],[SYMPTOM],insertion,N/A,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660772,9/15/2015 10:33:22,1738658041,9/15/2015 10:33:11,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],prepared,N/A,14,109,41,62,149,RO-may_prevent,820196-FS1,"High yielding ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP B) viruses were prepared by insertion of the HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE into the early region 3 (E3 region) of Ad4 or Ad7 vectors containing intact or largely deleted E3 regions.","ADENOVIRUS (AD), HEPATITIS B RECOMBINANT (AD HEP)",HEPATITIS B SURFACE ANTIGEN (HBSAG) GENE
788660773,9/15/2015 12:28:46,1738699304,9/15/2015 12:28:16,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],using,N/A,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 12:32:31,1738700534,9/15/2015 12:31:25,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],DIABETES MELLITUS,NONE,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 12:51:47,1738706522,9/15/2015 12:51:33,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",very good,very good,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 12:56:54,1738707762,9/15/2015 12:56:12,false,elite,1.0,28548715,USA,"","",38.95.108.245,[TREATS] [SYMPTOM],"[TREATS]
[SYMPTOM]",determining glycemic,n/a,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 12:59:26,1738708395,9/15/2015 12:58:59,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[SYMPTOM] [SIDE_EFFECT] [NONE],"[SYMPTOM]
[SIDE_EFFECT]
[NONE]",[TREATS],N/A,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 12:59:59,1738708504,9/15/2015 12:59:39,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[TREATS],[TREATS],(FPG),none,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 13:02:35,1738709252,9/15/2015 13:00:53,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],TYPE 2 DIABETES MELLITUS INSULIN glycemic control.,n/a,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 13:04:06,1738709605,9/15/2015 13:02:52,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[NONE],[NONE],N/A,They are both nouns describing the test subject with no obvious relation.,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 13:15:29,1738712670,9/15/2015 13:15:07,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],not using,n/a,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 13:26:19,1738716270,9/15/2015 13:25:42,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[TREATS],[TREATS],TYPE 2 DIABETES MELLITUS who are not using INSULIN,N/A,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 13:38:42,1738721710,9/15/2015 13:38:01,false,bitcoinget,1.0,31256687,USA,NY,Poughkeepsie,67.82.252.135,[OTHER],[OTHER],not using,n/a,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 13:54:08,1738725381,9/15/2015 13:53:41,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[TREATS],[TREATS],TYPE 2 DIABETES MELLITUS INSULIN,n/a,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 14:03:04,1738727523,9/15/2015 14:02:44,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[TREATS],[TREATS],using,n/a,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 14:25:54,1738733950,9/15/2015 14:24:32,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[TREATS],[TREATS],who are not using,N/A,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660773,9/15/2015 14:38:05,1738737041,9/15/2015 14:37:41,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[CAUSES] [PREVENTS] [NONE],"[PREVENTS]
[CAUSES]
[NONE]",A,Very good,17,60,41,40,67,RO-may_treat,820076-FS1,In patients with TYPE 2 DIABETES MELLITUS who are not using INSULIN how do fasting plasma glucose (FPG) measurements compare with those of glycosylated hemoglobin (HbA 1c ) in determining glycemic control.,TYPE 2 DIABETES MELLITUS,INSULIN
788660774,9/15/2015 09:24:38,1738639228,9/15/2015 09:24:13,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],treatment of,N/A,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 09:37:03,1738642812,9/15/2015 09:36:09,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 09:45:20,1738645380,9/15/2015 09:44:47,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[OTHER],[OTHER],in the treatment of,n/a,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 09:46:56,1738645763,9/15/2015 09:46:16,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],in the treatment of,N/A,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 09:53:07,1738647464,9/15/2015 09:52:53,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treatment,n/a,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 09:57:39,1738648604,9/15/2015 09:57:02,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatment,N/A,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 10:01:00,1738649407,9/15/2015 10:00:17,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[IS_A],[IS_A],treatment,N/A,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 10:04:49,1738650526,9/15/2015 10:03:48,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],treatment of,N/A,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 10:06:25,1738650968,9/15/2015 10:06:09,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],treatment,N/A,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 10:07:32,1738651283,9/15/2015 10:06:20,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],treatment,N/a,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 10:10:18,1738652095,9/15/2015 10:09:47,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],treatment,N/A,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 10:15:05,1738653473,9/15/2015 10:14:23,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],LMW HEPARIN treatment PULMONARY EMBOLISM,cure,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 10:16:32,1738653913,9/15/2015 10:16:11,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],in the treatment of,n/a,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 10:24:45,1738656034,9/15/2015 10:24:34,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],treatment,N/A,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660774,9/15/2015 10:33:21,1738658037,9/15/2015 10:32:56,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[TREATS],[TREATS],treatment,N/A,204,169,222,221,176,RO-may_prevent,820233-FS1,"211 ,   226 ,   242 ,   243 ,   244 ,   245 ,   246 ,   247 ,   248 ,   249 ,   250 ,   251 ,   252 ,   348 ,   350 ,   372 ,   432 ,   440  Used short term with an LMW HEPARIN in the treatment of DVT or PULMONARY EMBOLISM following MI in hospitalized patients.",PULMONARY EMBOLISM,HEPARIN
788660775,9/15/2015 09:31:30,1738640873,9/15/2015 09:31:08,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],requiring,N/A,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 09:52:36,1738647296,9/15/2015 09:52:15,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[ASSOCIATED_WITH],[ASSOCIATED_WITH],requiring,n/a,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 09:55:25,1738648062,9/15/2015 09:54:26,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[ASSOCIATED_WITH],[ASSOCIATED_WITH],requiring replacement,N/A,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 09:59:17,1738648966,9/15/2015 09:58:49,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[TREATS],[TREATS],treated,n/a,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 09:59:46,1738649110,9/15/2015 09:58:23,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],requiring replacement occurred,N/A,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 10:07:53,1738651380,9/15/2015 10:07:21,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[SYMPTOM],[SYMPTOM],replacement occurred,N/A,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 10:13:18,1738652965,9/15/2015 10:12:21,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],HYPOTHYROIDISM requiring LEVOTHYROXINE replacement,N/A,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 10:14:35,1738653361,9/15/2015 10:13:44,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[ASSOCIATED_WITH],[ASSOCIATED_WITH],requiring replacement,N/A,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 10:14:43,1738653394,9/15/2015 10:14:18,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],treated,N/A,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 10:20:45,1738654870,9/15/2015 10:20:24,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],requiring,N/a,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 10:23:33,1738655670,9/15/2015 10:22:45,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[PART_OF],[PART_OF],requiring,N/A,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 10:25:40,1738656273,9/15/2015 10:25:17,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],HYPOTHYROIDISM requiring LEVOTHYROXINE replacement,N/A,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 10:25:55,1738656321,9/15/2015 10:25:07,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[CAUSES],[CAUSES],"glucocorticoids, HYPOTHYROIDISM LEVOTHYROXINE",make it go,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 10:27:57,1738656717,9/15/2015 10:27:46,false,elite,1.0,30659754,USA,"","",162.250.145.204,[TREATS],[TREATS],treated,N/A,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660775,9/15/2015 10:33:09,1738657977,9/15/2015 10:32:57,false,elite,1.0,30659677,USA,"","",162.252.172.126,[ASSOCIATED_WITH],[ASSOCIATED_WITH],requiring,N/A,228,253,242,241,266,RO-may_prevent,820355-FS1,"In a prospective, controlled study of 60 patients with type II amiodarone induced thyrotoxicosis treated with glucocorticoids compared with 60 patients with subacute thyroiditis similarly treated with glucocorticoids, permanent HYPOTHYROIDISM requiring LEVOTHYROXINE replacement occurred in 17% of patients with type II amiodarone induced thyrotoxicosis compared with 5% of patients with subacute thyroiditis ( 111.",HYPOTHYROIDISM,LEVOTHYROXINE
788660776,9/15/2015 10:46:59,1738661539,9/15/2015 10:46:45,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],TREATMENT,N/A,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 10:55:48,1738663555,9/15/2015 10:55:33,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],TREATMENT,N/A,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 10:59:05,1738664226,9/15/2015 10:58:47,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],TREATMENT,Treat,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 11:01:34,1738664796,9/15/2015 11:00:52,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],TREATMENT,N/a,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 11:06:55,1738665968,9/15/2015 11:06:42,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],approved,N/A,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 11:39:41,1738680988,9/15/2015 11:39:19,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[TREATS],[TREATS],TREATMENT OF,N/A,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 11:42:17,1738682301,9/15/2015 11:41:17,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[TREATS],[TREATS],TREATMENT OF,N/A,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 11:43:31,1738682744,9/15/2015 11:42:51,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[TREATS],[TREATS],Acyclovir is licensed FOR TREATMENT OF VARICELLA ZOSTER,N/A,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 12:02:59,1738690442,9/15/2015 12:02:45,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],TREATMENT,n/a,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 12:23:44,1738697799,9/15/2015 12:23:25,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],TREATMENT,N/A,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 12:24:51,1738698081,9/15/2015 12:24:05,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],VARICELLA HERPES ZOSTER,NONE,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 12:44:37,1738704642,9/15/2015 12:43:43,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [NONE],"[TREATS]
[NONE]",none,very good,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 12:46:45,1738705340,9/15/2015 12:45:47,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[TREATS],[TREATS],licensed FOR TREATMENT,N/A,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 12:48:07,1738705615,9/15/2015 12:47:39,false,elite,1.0,28548715,USA,"","",38.95.108.245,[TREATS],[TREATS],TREATMENT,n/a,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660776,9/15/2015 12:51:45,1738706518,9/15/2015 12:50:47,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],Acyclovir FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,n/a,22,85,48,65,94,RO-may_prevent,820356-FS1,"Acyclovir is licensed FOR TREATMENT OF VARICELLA AND HERPES ZOSTER and acyclovir, valACYCLOVIR and famciclovir are approved for herpes zoster.",FOR TREATMENT OF VARICELLA AND HERPES ZOSTER,ACYCLOVIR
788660777,9/15/2015 10:37:05,1738658932,9/15/2015 10:36:54,false,elite,1,30659677,USA,"","",162.252.172.126,[TREATS],[TREATS],treatment,N/A,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 10:38:08,1738659219,9/15/2015 10:37:55,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],used for initial treatment,N/A,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 10:40:19,1738659908,9/15/2015 10:39:50,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH] [TREATS],"[TREATS]
[ASSOCIATED_WITH]",olmesartan/HYDROCHLOROTHIAZIDE treatment HYPERTENSION,n/a,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 10:42:19,1738660379,9/15/2015 10:41:44,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[CONTRAINDICATES],[CONTRAINDICATES],should not be used for initial treatment,N/A,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 10:42:36,1738660422,9/15/2015 10:42:25,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[TREATS],[TREATS],treatment,N/A,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 10:44:43,1738660928,9/15/2015 10:44:19,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[TREATS],[TREATS],Fixed,Treat,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 10:50:47,1738662365,9/15/2015 10:50:05,false,prodege,1,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],treatment,N/a,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 10:51:00,1738662392,9/15/2015 10:50:49,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],treatment,N/A,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 11:01:31,1738664771,9/15/2015 11:01:19,false,elite,1.0,30659615,USA,"","",162.250.145.234,[TREATS],[TREATS],treatment,N/A,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 11:06:59,1738665991,9/15/2015 11:05:07,false,points4rewards,1,20113482,USA,PA,Philadelphia,162.208.49.45,[CONTRAINDICATES],[CONTRAINDICATES],should not be used for initial treatment,N/A,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 11:19:15,1738670575,9/15/2015 11:18:46,false,instagc,1,31184650,USA,IA,Mason City,173.26.179.94,[TREATS],[TREATS],olmesartan/HYDROCHLOROTHIAZIDE should not be used for treatment of HYPERTENSION,N/a,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 11:23:44,1738673317,9/15/2015 11:22:57,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[CONTRAINDICATES],[CONTRAINDICATES],should not be used for treatment,N/A,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 11:27:37,1738675450,9/15/2015 11:26:45,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[CONTRAINDICATES],[CONTRAINDICATES],olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used,N/A,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 11:52:18,1738686895,9/15/2015 11:51:40,false,elite,1,31883685,GBR,"","",79.66.254.237,[CONTRAINDICATES],[CONTRAINDICATES],should not be used,n/a,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660777,9/15/2015 12:10:31,1738692684,9/15/2015 12:09:08,false,neodev,1,33758777,USA,"","",38.95.108.251,[CONTRAINDICATES],[CONTRAINDICATES],used,N/A,180,108,192,191,127,RO-may_treat,820084-FS1,Dosage and Administration  General  Hypertension  •  Fixed combination olmesartan/amlodipine and olmesartan/HYDROCHLOROTHIAZIDE tablets should not be used for initial treatment of HYPERTENSION,HYPERTENSION,HYDROCHLOROTHIAZIDE
788660778,9/15/2015 09:25:58,1738639599,9/15/2015 09:25:19,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],treatment of,N/A,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 09:38:26,1738643292,9/15/2015 09:37:45,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],treatment,N/A,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 09:46:17,1738645584,9/15/2015 09:45:55,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[OTHER],[OTHER],should be used,n/a,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 09:49:34,1738646340,9/15/2015 09:48:01,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[CONTRAINDICATES],[CONTRAINDICATES],should be used only,N/A,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 09:54:21,1738647786,9/15/2015 09:53:54,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used,n/a,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 09:58:54,1738648886,9/15/2015 09:57:47,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],should be used,N/A,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 10:00:05,1738649189,9/15/2015 09:58:49,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],treatment,N/A,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 10:02:04,1738649734,9/15/2015 10:01:32,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[TREATS],[TREATS],should be used,N/A,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 10:07:20,1738651238,9/15/2015 10:06:59,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],treatment,N/A,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 10:09:26,1738651800,9/15/2015 10:08:49,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[TREATS],[TREATS],treatment,N/a,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 10:12:16,1738652728,9/15/2015 10:11:12,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[CAUSES],[CAUSES],is likely most likely caused,N/A,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 10:16:13,1738653803,9/15/2015 10:15:38,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],gonococcal CHLAMYDIAL levOFLOXACIN,prevent,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 10:18:38,1738654364,9/15/2015 10:17:39,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS] [OTHER],"[TREATS]
[OTHER]",levOFLOXACIN should be used only if not caused by gonorrhea,n/a,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 10:25:13,1738656142,9/15/2015 10:24:59,false,elite,1.0,30659754,USA,"","",162.250.145.204,[CAUSES],[CAUSES],INFECTION,N/A,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660778,9/15/2015 10:31:16,1738657509,9/15/2015 10:30:45,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],levOFLOXACIN should be used only,N/A,81,160,101,100,169,RO-may_treat,820086-FS1,"672  For empiric treatment of epididymitis   +   , especially when gonococcal or CHLAMYDIAL INFECTION is likely (e.g., in those   577 ,   672   Ofloxacin or levOFLOXACIN should be used  only  if epididymitis is not caused by gonorrhea (i.e., results of culture or nucleic acid amplification testing are negative for  N. gonorrhoeae ) or is most likely caused by sexually transmitted enteric bacteria.",CHLAMYDIAL INFECTION,OFLOXACIN
788660779,9/15/2015 10:38:43,1738659375,9/15/2015 10:38:29,false,elite,1.0,30659677,USA,"","",162.252.172.126,[PREVENTS],[PREVENTS],decrease,N/A,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 10:41:01,1738660060,9/15/2015 10:40:39,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 10:42:30,1738660400,9/15/2015 10:42:07,false,clixsense,1.0,19162475,GBR,P8,Trowbridge,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 10:44:16,1738660830,9/15/2015 10:44:02,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 10:48:55,1738661942,9/15/2015 10:48:04,false,clixsense,1.0,33115750,GBR,I3,Rochester,90.222.106.192,[ASSOCIATED_WITH],[ASSOCIATED_WITH],decrease,N/A,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 10:51:19,1738662521,9/15/2015 10:50:27,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[SIDE_EFFECT],[SIDE_EFFECT],affects,Side effect,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 10:52:49,1738662808,9/15/2015 10:52:36,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[TREATS],[TREATS],decrease,N/A,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 10:55:23,1738663435,9/15/2015 10:54:20,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[SIDE_EFFECT],[SIDE_EFFECT],per se affects the insulin stimulated glucose transport,N/a,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 11:03:50,1738665279,9/15/2015 11:03:34,false,elite,1.0,30659615,USA,"","",162.250.145.234,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 11:26:38,1738674912,9/15/2015 11:24:30,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[OTHER],[OTHER],"In conclusion, (a) (b) (c)",N/A,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 11:32:45,1738678139,9/15/2015 11:29:52,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[ASSOCIATED_WITH],[ASSOCIATED_WITH],affects,N/A,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 11:34:16,1738678783,9/15/2015 11:33:17,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[ASSOCIATED_WITH],[ASSOCIATED_WITH],INSULIN GLUCOSE and HYPERGLYCEMIA,N/A,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 11:56:24,1738688488,9/15/2015 11:55:25,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[NONE],[NONE],n/a,just part of subect,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 12:14:12,1738694259,9/15/2015 12:13:03,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[TREATS],[TREATS],INSULIN STIMULATED GLUCOSE,NONE,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660779,9/15/2015 12:18:35,1738696083,9/15/2015 12:17:01,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[SIDE_EFFECT],[SIDE_EFFECT],defect,N/A,288,242,301,300,278,RO-may_treat,820120-FS1,"In conclusion, in streptozocin diabetes (a) reduction of intrinsic activity plays a major and early role in the impairment of basal glucose transport; (b) a defect in transporter translocation is the mechanism responsible for the decrease in INSULIN STIMULATED GLUCOSE TRANSPORT; and (c) HYPERGLYCEMIA per se affects the insulin stimulated glucose transport by altering the transporter translocation.",HYPERGLYCEMIA,INSULIN STIMULATED GLUCOSE TRANSPORT
788660780,9/15/2015 09:29:45,1738640439,9/15/2015 09:29:23,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[LOCATION],[LOCATION],inserted,N/A,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 09:49:05,1738646234,9/15/2015 09:48:14,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[TREATS],[TREATS],inserted,N/A,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 09:50:49,1738646826,9/15/2015 09:50:26,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[LOCATION],[LOCATION],prepared in,n/a,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 09:55:55,1738648200,9/15/2015 09:55:03,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(experimental group) (control group.,N/A,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 09:57:30,1738648569,9/15/2015 09:57:10,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[LOCATION],[LOCATION],in,n/a,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 10:05:36,1738650750,9/15/2015 10:05:09,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],(experimental group),N/A,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 10:08:28,1738651564,9/15/2015 10:07:15,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities",N/A,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 10:11:21,1738652481,9/15/2015 10:10:32,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],was inserted,N/A,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 10:12:49,1738652867,9/15/2015 10:11:59,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[ASSOCIATED_WITH],[ASSOCIATED_WITH],group.,N/A,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 10:18:49,1738654401,9/15/2015 10:18:20,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[NONE],[NONE],N/a,Prepared,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 10:19:45,1738654625,9/15/2015 10:18:26,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were prepared in,N/A,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 10:21:23,1738655053,9/15/2015 10:20:37,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[PREVENTS],[PREVENTS],CLASS V CAVITIES FLUORIDE CONTAINING AMALGAM conventional amalgam,cure,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 10:23:32,1738655657,9/15/2015 10:22:57,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],FLUORIDE CONTAINING AMALGAM was inserted,n/A,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 10:27:03,1738656521,9/15/2015 10:26:51,false,elite,1.0,30659754,USA,"","",162.250.145.204,[SYMPTOM],[SYMPTOM],prepared,N/A,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660780,9/15/2015 10:32:34,1738657841,9/15/2015 10:32:23,false,elite,1.0,30659677,USA,"","",162.252.172.126,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],extracted,N/A,0,60,16,15,87,RO-may_prevent,820363-FS1,"CLASS V CAVITIES were prepared in 90 extracted premolars, a FLUORIDE CONTAINING AMALGAM was inserted in 45 cavities (experimental group) and a conventional amalgam in 45 cavities (control group.",CLASS V CAVITIES,FLUORIDE CONTAINING AMALGAM
788660781,9/15/2015 10:46:07,1738661314,9/15/2015 10:45:54,false,elite,1.0,33453990,USA,VA,Manassas,207.244.89.75,[CAUSES],[CAUSES],"established,",N/A,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 10:55:03,1738663339,9/15/2015 10:54:49,false,elite,1.0,30659551,USA,VA,Manassas,207.244.89.77,[CAUSES],[CAUSES],increasing,N/A,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 10:57:19,1738663859,9/15/2015 10:56:47,false,elite,1.0,34356654,USA,CA,San Jose,50.118.198.254,[PREVENTS],[PREVENTS],Resistance,Prevents,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 10:59:37,1738664339,9/15/2015 10:58:58,false,prodege,1.0,22031444,GBR,M4,Southampton,2.98.205.228,[TREATS],[TREATS],Resistance to methotrexate was developed,N/a,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 11:06:05,1738665785,9/15/2015 11:05:51,false,elite,1.0,30659615,USA,"","",162.250.145.234,[CAUSES],[CAUSES],developed,N/A,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 11:38:18,1738680393,9/15/2015 11:37:32,false,prodege,1.0,27934334,GBR,C8,Croydon,81.159.60.206,[OTHER],[OTHER],Resistance to,N/A,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 11:39:51,1738681049,9/15/2015 11:37:12,false,points4rewards,1.0,20113482,USA,PA,Philadelphia,162.208.49.45,[SIDE_EFFECT],[SIDE_EFFECT],Resistance developed by continuous exposure of,N/A,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 11:41:31,1738681910,9/15/2015 11:40:40,false,neodev,1.0,12115558,USA,OH,Twinsburg,98.27.164.131,[MANIFESTATION],[MANIFESTATION],LEUKEMIA cells increasing concentrations of METHOTREXATE,N/A,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 12:00:45,1738689811,9/15/2015 12:00:21,false,elite,1.0,31883685,GBR,"","",79.66.254.237,[TREATS],[TREATS],Resistance,n/a,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 12:21:52,1738697100,9/15/2015 12:21:14,false,clixsense,1.0,17950689,GBR,L9,Sheffield,146.200.192.103,[SYMPTOM],[SYMPTOM],LEUKEMIA,NONE,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 12:22:23,1738697283,9/15/2015 12:21:26,false,neodev,1.0,33758777,USA,"","",38.95.108.251,[TREATS],[TREATS],exposure,N/A,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 12:42:20,1738704017,9/15/2015 12:41:27,false,neodev,1.0,30581619,USA,CA,San Jose,50.118.172.208,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION] [MANIFESTATION] [ASSOCIATED_WITH] [IS_A] [NONE],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[MANIFESTATION]
[ASSOCIATED_WITH]
[IS_A]
[NONE]",none,very good,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 12:43:22,1738704194,9/15/2015 12:40:24,false,tremorgames,1.0,32655637,CAN,ON,Markham,135.23.223.26,[OTHER] [TREATS],"[TREATS]
[OTHER]",Resistance,N/A,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 12:45:29,1738704899,9/15/2015 12:43:47,false,clixsense,1,7074645,USA,"","",73.221.254.240,[PREVENTS],[PREVENTS],continuous exposure,i selected in step 1,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660781,9/15/2015 12:50:47,1738706235,9/15/2015 12:48:21,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[TREATS],[TREATS],Resistance to methotrexate by continuous exposure murine LEUKEMIA cells in was stable.,n/a,79,135,87,86,147,RO-may_treat,820124-FS1,"Resistance to methotrexate was developed by continuous exposure of P388 murine LEUKEMIA cells in vitro to increasing concentrations of METHOTREXATE up to 1 X 10( 7) M. Once established, the resistance to methotrexate was stable.",LEUKEMIA,METHOTREXATE
788660782,9/15/2015 13:03:36,1738709491,9/15/2015 13:03:22,false,neodev,1.0,33701549,USA,CA,San Jose,23.27.248.252,[TREATS] [SYMPTOM] [ASSOCIATED_WITH] [NONE],"[TREATS]
[SYMPTOM]
[ASSOCIATED_WITH]
[NONE]",[PREVENTS],N/A,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 13:04:33,1738709706,9/15/2015 13:03:53,false,elite,1.0,28548715,USA,"","",38.95.108.245,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HEPARIN,n/a,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 13:05:07,1738709864,9/15/2015 13:04:44,false,zoombucks,1.0,4711962,CAN,ON,Markham,174.88.29.138,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HEPARIN,none,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 13:22:03,1738714782,9/15/2015 13:21:43,false,instagc,1.0,13581319,USA,IL,Trenton,208.70.36.12,[TREATS],[TREATS],Safety of withholding HEPARIN,n/a,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 13:31:59,1738717730,9/15/2015 13:30:59,false,gifthulk,1.0,18666417,USA,PA,Meadville,24.101.32.13,[SIDE_EFFECT],[SIDE_EFFECT],Safety withholding HEPARIN in pregnant women with VENOUS THROMBOEMBOLISM,n/a,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 13:34:27,1738718378,9/15/2015 13:33:54,false,neodev,1.0,31743852,GBR,H9,London,77.89.149.62,[CONTRAINDICATES],[CONTRAINDICATES],withholding HEPARIN pregnant women history of VENOUS THROMBOEMBOLISM,N/A,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 14:10:28,1738729342,9/15/2015 14:09:36,false,elite,1.0,30064988,GBR,G8,Huddersfield,92.29.158.223,[OTHER],[OTHER],Safety of withholding,n/a,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 14:29:29,1738734881,9/15/2015 14:28:55,false,instagc,1.0,32352104,USA,ME,Bangor,74.75.63.81,[ASSOCIATED_WITH],[ASSOCIATED_WITH],withholding HEPARIN pregnant women with history VENOUS THROMBOEMBOLISM,n/a,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 14:33:04,1738735736,9/15/2015 14:32:51,false,tremorgames,1.0,24449707,CAN,QC,Laval,96.20.14.148,[OTHER],[OTHER],with a history of,N/A,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 14:43:08,1738738574,9/15/2015 14:42:59,false,neodev,1.0,33895262,USA,VA,Mclean,63.141.204.167,[NONE],[NONE],N/A,N/A,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 14:52:16,1738741241,9/15/2015 14:51:26,false,prodege,1.0,33753166,CAN,ON,Toronto,173.206.80.252,[TREATS],[TREATS],Safety withholding,N/A,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 15:11:03,1738747938,9/15/2015 15:10:41,false,bitcoinget,1.0,21743413,USA,WA,Port Angeles,65.193.218.66,[OTHER],[OTHER],Safety of withholding,N/A,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 15:12:48,1738748760,9/15/2015 15:11:13,false,zoombucks,1.0,6744840,CAN,BC,Kelowna,174.4.58.160,[TREATS],[TREATS],HEPARIN in,N/A,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 15:18:18,1738751409,9/15/2015 15:18:06,false,neodev,1.0,34431172,CAN,AB,Edmonton,208.123.223.129,[LOCATION] [NONE],"[LOCATION]
[NONE]",no,no,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660782,9/15/2015 15:59:05,1738765130,9/15/2015 15:58:47,false,elite,1,31722487,USA,"","",73.128.252.24,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",in pregnant women,N/A,145,101,167,166,108,RO-may_prevent,820246-FS1,"2]  Brill Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C, et al. Safety of withholding HEPARIN in pregnant women with a history of VENOUS THROMBOEMBOLISM",VENOUS THROMBOEMBOLISM,HEPARIN
788660783,9/15/2015 09:30:11,1738640559,9/15/2015 09:29:45,false,neodev,1.0,32053642,GBR,I7,Newcastle Upon Tyne,92.23.136.205,[TREATS],[TREATS],effective as,N/A,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 09:50:39,1738646777,9/15/2015 09:49:06,false,clixsense,1.0,30681826,GBR,I9,Diss,31.49.71.254,[OTHER],[OTHER],is as effective as,N/A,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 09:51:10,1738646900,9/15/2015 09:50:50,false,neodev,1.0,15848372,AUS,02,Jannali,14.200.59.55,[OTHER],[OTHER],is as effective as,n/a,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 09:56:34,1738648322,9/15/2015 09:55:59,false,points4rewards,1.0,28703583,USA,"","",184.53.33.189,[TREATS],[TREATS],is as effective as,N/A,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 09:58:02,1738648707,9/15/2015 09:57:31,false,meprizescf,1.0,28483210,USA,WI,Minocqua,75.143.134.247,[IS_A],[IS_A],is,n/a,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 10:06:16,1738650924,9/15/2015 10:05:37,false,bitcoinget,1.0,20311164,NLD,09,Utrecht,84.105.54.251,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is as effective as,N/A,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 10:09:48,1738651932,9/15/2015 10:08:30,false,gifthunterclub,1.0,24043308,GBR,"","",94.102.147.250,[TREATS],[TREATS],facilitating cutaneous healing,N/A,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 10:11:42,1738652552,9/15/2015 10:11:22,false,neodev,1.0,30588889,NLD,07,Amsterdam,77.248.175.222,[TREATS],[TREATS],is as effective as,N/A,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 10:13:16,1738652964,9/15/2015 10:12:51,false,neodev,1.0,20961587,NLD,05,Maastricht,84.26.48.136,[TREATS],[TREATS],healing,N/A,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 10:19:18,1738654522,9/15/2015 10:18:51,false,prodege,1.0,16101132,GBR,F9,Hayes,2.216.28.167,[ASSOCIATED_WITH],[ASSOCIATED_WITH],effective,N/a,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 10:20:28,1738654806,9/15/2015 10:19:46,false,pocketmoneygpt,1.0,21432964,GBR,F8,Borehamwood,81.159.185.70,[TREATS],[TREATS],is as effective as,N/A,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 10:23:07,1738655528,9/15/2015 10:21:24,false,neodev,1.0,33644825,USA,IL,Chicago,65.60.20.67,[TREATS],[TREATS],HERPES ZOSTER valacyclovir FAMCICLOVIR healing of zoster,treat,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 10:24:07,1738655841,9/15/2015 10:23:34,false,prodege,1.0,14848125,GBR,V8,Airdrie,86.151.77.161,[TREATS],[TREATS],is as effective as FAMCICLOVIR,N/A,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 10:27:17,1738656558,9/15/2015 10:27:05,false,elite,1.0,30659754,USA,"","",162.250.145.204,[PREVENTS],[PREVENTS],effective,N/A,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
788660783,9/15/2015 10:32:51,1738657910,9/15/2015 10:32:25,false,instagc,1.0,18960682,GBR,U2,Annan,92.18.213.181,[TREATS],[TREATS],In HERPES ZOSTER is as effective as FAMCICLOVIR,N/A,3,49,16,15,60,RO-may_prevent,820367-FS1,In HERPES ZOSTER valacyclovir is as effective as FAMCICLOVIR and more effective than either placebo or acyclovir at facilitating cutaneous healing and healing of zoster associated pain and post herpetic neuralgia.,HERPES ZOSTER,FAMCICLOVIR
